Search Results For:
- No search criteria provided
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Termination & withdrawal
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Alnylam Pharmaceuticals - University of British Columbia- AlCana Technology, Sponsored Research Agreement
2009
Academic institution
Industry
Industry
Drug
Vaccine
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Product development partnership
Vaccine
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
AUTM Model Inter-Institutional Research Collaboration Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Business model | Benefit sharing
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
AUTM Preliminary Patent Management Agreement
2013
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
2020
Funder
Industry
Industry
Diagnostic
Drug
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Product supply
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Term & termination | Term of agreement
BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement
2013
Academic institution
Industry
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Industry
Drug
Preclinical
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gates Foundation - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
2017
Funder
Industry
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Termination & withdrawal
Gates Foundation - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gates Foundation - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Representations & Warranties
- Term & termination | Term of agreement
Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Product supply
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Representations & Warranties
Boston University Startup Exclusive License Template
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Access plans & principles
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CARB-X Research Subaward Agreement
2019
Academic institution
Funder
Industry
Funder
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Termination & withdrawal
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
Government
Industry
Funder
Government
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Cellscript - BioNTech mRNA Technology Patent Sublicense
2016
Industry
Vaccine
Preclinical
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Multilateral organization
Diagnostic
Commercialization
- Equitable Access | Affordable pricing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
DNDi Template Development Collaboration and License Agreement
2023
Academic institution
Industry
Product development partnership
Industry
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
DNDi Template Research Collaboration and License Agreement
2023
Academic institution
Industry
Product development partnership
Industry
Product development partnership
Drug
Discovery/Concept
Preclinical
Preclinical
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
DNDi - BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement
2009
Industry
Product development partnership
Product development partnership
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
WHO - Manufacturer, Ebola Products Collaboration LOA Template
2015
Multilateral organization
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
2021
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
DNDi/GARDP - Entasis, Gonorrhoea Medication, Collaboration Agreement
2017
Industry
Product development partnership
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
FIND Sample Funding Terms and Conditions
2021
Academic institution
Industry
Product development partnership
Industry
Product development partnership
Diagnostic
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Representations & Warranties
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Funder Development Partnering Agreement Template
2018
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
2015
Funder
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
Gates Foundation Sample Grant Terms & Conditions
2019
Academic institution
Funder
Industry
Product development partnership
Funder
Industry
Product development partnership
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gilead - Indian Generic Manufacturers, HCV License Agreement
2014
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Commercialization
Field Testing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of IP
- Liability | Representations & Warranties
Lambert Toolkit, Consortium Agreement D Template
2019
Academic institution
Industry
Industry
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Termination & withdrawal
Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
2014
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
- Equitable Access | Ensuring continuity
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MPP - AbbVie, HIV Antiretroviral License Agreement
2016
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - AbbVie, HIV Antiretroviral Sublicense Agreement
2014
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
2022
Industry
Multilateral organization
Multilateral organization
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MPP - BMS - Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
2016
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - BMS Sublicense & Tech Transfer Agreement
2017
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
2018
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MPP - Pfizer, Sutezolid License Agreement
2019
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
2022
Industry
Multilateral organization
Multilateral organization
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MPP - University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
2015
Academic institution
Multilateral organization
Multilateral organization
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
MPP - ViiV, Dolutegravir License Agreement
2016
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
Merck - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement
2022
Government
Industry
Industry
Drug
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
NIH - Non-Profit, Model License Agreement Terms
2017
Government
Multilateral organization
Product development partnership
Multilateral organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
NIH - MPP, COVID-19 Patent and Biological Material License Agreement
2022
Government
Multilateral organization
Multilateral organization
Diagnostic
Drug
Vaccine
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Liability | Representations & Warranties
- Term & termination | Term of agreement
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Academic Institution - Company, Research Collaboration Agreement
2016
Academic institution
Industry
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Access plans & principles
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Liability | Indemnification & liability
Shionogi - GARDP, Cefiderocol License Agreement
2022
Industry
Product development partnership
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UnitaidExplore Sample Funding Terms and Conditions
2020
Academic institution
Funder
Industry
Product development partnership
Funder
Industry
Product development partnership
Device
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
2021
Academic institution
Multilateral organization
Multilateral organization
Drug
Preclinical
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
2010
Funder
Industry
Industry
Drug
Discovery/Concept
Preclinical
Preclinical
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
WHO Confidential Disclosure Agreement Template
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Intellectual Property | Ownership of IP
- Liability | Representations & Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
GHIAA2019\MapguideSearch Object ( [search_parameters] => [filters] => Array ( ) [child_filters] => Array ( ) [agreement_args] => [provision_args] => Array ( [post_type] => provision_document [posts_per_page] => -1 ) [text_agreement_args] => [text_provision_args] => [agreement_ids] => Array ( ) [agreement_q_rslts] => [provision_q_rslts] => WP_Query Object ( [query] => Array ( [post_type] => provision_document [posts_per_page] => -1 ) [query_vars] => Array ( [post_type] => provision_document [posts_per_page] => -1 [error] => [m] => [p] => 0 [post_parent] => [subpost] => [subpost_id] => [attachment] => [attachment_id] => 0 [name] => [pagename] => [page_id] => 0 [second] => [minute] => [hour] => [day] => 0 [monthnum] => 0 [year] => 0 [w] => 0 [category_name] => [tag] => [cat] => [tag_id] => [author] => [author_name] => [feed] => [tb] => [paged] => 0 [meta_key] => [meta_value] => [preview] => [s] => [sentence] => [title] => [fields] => [menu_order] => [embed] => [category__in] => Array ( ) [category__not_in] => Array ( ) [category__and] => Array ( ) [post__in] => Array ( ) [post__not_in] => Array ( ) [post_name__in] => Array ( ) [tag__in] => Array ( ) [tag__not_in] => Array ( ) [tag__and] => Array ( ) [tag_slug__in] => Array ( ) [tag_slug__and] => Array ( ) [post_parent__in] => Array ( ) [post_parent__not_in] => Array ( ) [author__in] => Array ( ) [author__not_in] => Array ( ) [search_columns] => Array ( ) [ignore_sticky_posts] => [suppress_filters] => [cache_results] => 1 [update_post_term_cache] => 1 [update_menu_item_cache] => [lazy_load_term_meta] => 1 [update_post_meta_cache] => 1 [nopaging] => 1 [comments_per_page] => 50 [no_found_rows] => [order] => DESC ) [tax_query] => WP_Tax_Query Object ( [queries] => Array ( ) [relation] => AND [table_aliases:protected] => Array ( ) [queried_terms] => Array ( ) [primary_table] => wpry_posts [primary_id_column] => ID ) [meta_query] => WP_Meta_Query Object ( [queries] => Array ( ) [relation] => [meta_table] => [meta_id_column] => [primary_table] => [primary_id_column] => [table_aliases:protected] => Array ( ) [clauses:protected] => Array ( ) [has_or_relation:protected] => ) [date_query] => [request] => SELECT wpry_posts.* FROM wpry_posts WHERE 1=1 AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled'))) ORDER BY wpry_posts.post_date DESC [posts] => Array ( [0] => WP_Post Object ( [ID] => 9894 [post_author] => 5 [post_date] => 2023-04-20 12:27:42 [post_date_gmt] => 2023-04-20 12:27:42 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-19 [to_ping] => [pinged] => [post_modified] => 2023-06-05 15:00:14 [post_modified_gmt] => 2023-06-05 15:00:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9894 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 9893 [post_author] => 5 [post_date] => 2023-04-20 12:20:05 [post_date_gmt] => 2023-04-20 12:20:05 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-18 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:44:02 [post_modified_gmt] => 2023-04-28 13:44:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9893 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 9892 [post_author] => 5 [post_date] => 2023-04-20 12:00:13 [post_date_gmt] => 2023-04-20 12:00:13 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:11:22 [post_modified_gmt] => 2023-04-20 12:11:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9892 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 9891 [post_author] => 5 [post_date] => 2023-04-20 08:44:23 [post_date_gmt] => 2023-04-20 08:44:23 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:43:41 [post_modified_gmt] => 2023-04-28 13:43:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9891 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 9890 [post_author] => 5 [post_date] => 2023-04-20 08:28:58 [post_date_gmt] => 2023-04-20 08:28:58 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-04-20 08:28:58 [post_modified_gmt] => 2023-04-20 08:28:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9890 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [5] => WP_Post Object ( [ID] => 9889 [post_author] => 5 [post_date] => 2023-04-20 08:26:21 [post_date_gmt] => 2023-04-20 08:26:21 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-04-20 08:26:21 [post_modified_gmt] => 2023-04-20 08:26:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9889 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [6] => WP_Post Object ( [ID] => 9888 [post_author] => 5 [post_date] => 2023-04-20 08:15:26 [post_date_gmt] => 2023-04-20 08:15:26 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-04-20 14:16:07 [post_modified_gmt] => 2023-04-20 14:16:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9888 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [7] => WP_Post Object ( [ID] => 9886 [post_author] => 5 [post_date] => 2023-04-20 08:00:35 [post_date_gmt] => 2023-04-20 08:00:35 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-04-20 08:00:35 [post_modified_gmt] => 2023-04-20 08:00:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9886 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [8] => WP_Post Object ( [ID] => 9885 [post_author] => 5 [post_date] => 2023-04-19 15:03:20 [post_date_gmt] => 2023-04-19 15:03:20 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-04-20 14:17:33 [post_modified_gmt] => 2023-04-20 14:17:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9885 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [9] => WP_Post Object ( [ID] => 9884 [post_author] => 5 [post_date] => 2023-04-19 14:28:15 [post_date_gmt] => 2023-04-19 14:28:15 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-04-19 14:28:15 [post_modified_gmt] => 2023-04-19 14:28:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9884 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [10] => WP_Post Object ( [ID] => 9883 [post_author] => 5 [post_date] => 2023-04-19 13:59:07 [post_date_gmt] => 2023-04-19 13:59:07 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-04-20 14:14:49 [post_modified_gmt] => 2023-04-20 14:14:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9883 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [11] => WP_Post Object ( [ID] => 9882 [post_author] => 5 [post_date] => 2023-04-19 13:38:50 [post_date_gmt] => 2023-04-19 13:38:50 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-04-19 13:38:50 [post_modified_gmt] => 2023-04-19 13:38:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9882 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [12] => WP_Post Object ( [ID] => 9881 [post_author] => 5 [post_date] => 2023-04-19 13:28:03 [post_date_gmt] => 2023-04-19 13:28:03 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-04-19 13:28:03 [post_modified_gmt] => 2023-04-19 13:28:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9881 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [13] => WP_Post Object ( [ID] => 9880 [post_author] => 5 [post_date] => 2023-04-19 13:15:50 [post_date_gmt] => 2023-04-19 13:15:50 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-04-19 13:15:50 [post_modified_gmt] => 2023-04-19 13:15:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9880 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [14] => WP_Post Object ( [ID] => 9879 [post_author] => 5 [post_date] => 2023-04-19 13:00:06 [post_date_gmt] => 2023-04-19 13:00:06 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-05-17 09:58:35 [post_modified_gmt] => 2023-05-17 09:58:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9879 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [15] => WP_Post Object ( [ID] => 9877 [post_author] => 5 [post_date] => 2023-04-19 11:54:25 [post_date_gmt] => 2023-04-19 11:54:25 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-20 14:10:10 [post_modified_gmt] => 2023-04-20 14:10:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9877 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [16] => WP_Post Object ( [ID] => 9875 [post_author] => 5 [post_date] => 2023-04-19 10:41:01 [post_date_gmt] => 2023-04-19 10:41:01 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-19 10:46:20 [post_modified_gmt] => 2023-04-19 10:46:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9875 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [17] => WP_Post Object ( [ID] => 9874 [post_author] => 5 [post_date] => 2023-04-18 15:17:41 [post_date_gmt] => 2023-04-18 15:17:41 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-20 14:12:02 [post_modified_gmt] => 2023-04-20 14:12:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9874 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [18] => WP_Post Object ( [ID] => 9873 [post_author] => 5 [post_date] => 2023-04-18 14:52:22 [post_date_gmt] => 2023-04-18 14:52:22 [post_content] => [post_title] => DNDi Template Development Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-development-collaboration-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-19 10:42:02 [post_modified_gmt] => 2023-04-19 10:42:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9873 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [19] => WP_Post Object ( [ID] => 9872 [post_author] => 5 [post_date] => 2023-04-18 13:17:39 [post_date_gmt] => 2023-04-18 13:17:39 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:32:14 [post_modified_gmt] => 2023-04-20 12:32:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9872 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [20] => WP_Post Object ( [ID] => 9871 [post_author] => 5 [post_date] => 2023-04-18 10:57:25 [post_date_gmt] => 2023-04-18 10:57:25 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:32:39 [post_modified_gmt] => 2023-04-20 12:32:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9871 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [21] => WP_Post Object ( [ID] => 9870 [post_author] => 5 [post_date] => 2023-04-18 10:46:43 [post_date_gmt] => 2023-04-18 10:46:43 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:32:58 [post_modified_gmt] => 2023-04-20 12:32:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9870 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [22] => WP_Post Object ( [ID] => 9869 [post_author] => 5 [post_date] => 2023-04-18 10:43:52 [post_date_gmt] => 2023-04-18 10:43:52 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:33:18 [post_modified_gmt] => 2023-04-20 12:33:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9869 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [23] => WP_Post Object ( [ID] => 9868 [post_author] => 5 [post_date] => 2023-04-18 10:40:41 [post_date_gmt] => 2023-04-18 10:40:41 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:34:07 [post_modified_gmt] => 2023-04-20 12:34:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9868 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [24] => WP_Post Object ( [ID] => 9867 [post_author] => 5 [post_date] => 2023-04-18 10:21:23 [post_date_gmt] => 2023-04-18 10:21:23 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:34:28 [post_modified_gmt] => 2023-04-20 12:34:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9867 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [25] => WP_Post Object ( [ID] => 9866 [post_author] => 5 [post_date] => 2023-04-18 10:10:55 [post_date_gmt] => 2023-04-18 10:10:55 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:34:57 [post_modified_gmt] => 2023-04-20 12:34:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9866 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [26] => WP_Post Object ( [ID] => 9865 [post_author] => 5 [post_date] => 2023-04-18 09:13:30 [post_date_gmt] => 2023-04-18 09:13:30 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:44:46 [post_modified_gmt] => 2023-04-28 13:44:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9865 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [27] => WP_Post Object ( [ID] => 9863 [post_author] => 5 [post_date] => 2023-04-18 08:21:11 [post_date_gmt] => 2023-04-18 08:21:11 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:35:40 [post_modified_gmt] => 2023-04-20 12:35:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9863 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [28] => WP_Post Object ( [ID] => 9864 [post_author] => 5 [post_date] => 2023-04-18 07:54:00 [post_date_gmt] => 2023-04-18 07:54:00 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:36:03 [post_modified_gmt] => 2023-04-20 12:36:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9864 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [29] => WP_Post Object ( [ID] => 9862 [post_author] => 5 [post_date] => 2023-04-17 14:28:56 [post_date_gmt] => 2023-04-17 14:28:56 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:36:23 [post_modified_gmt] => 2023-04-20 12:36:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9862 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [30] => WP_Post Object ( [ID] => 9861 [post_author] => 5 [post_date] => 2023-04-17 14:18:47 [post_date_gmt] => 2023-04-17 14:18:47 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:36:43 [post_modified_gmt] => 2023-04-20 12:36:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9861 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [31] => WP_Post Object ( [ID] => 9860 [post_author] => 5 [post_date] => 2023-04-14 14:35:29 [post_date_gmt] => 2023-04-14 14:35:29 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:37:05 [post_modified_gmt] => 2023-04-20 12:37:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9860 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [32] => WP_Post Object ( [ID] => 9859 [post_author] => 5 [post_date] => 2023-04-14 13:08:09 [post_date_gmt] => 2023-04-14 13:08:09 [post_content] => [post_title] => DNDi Template Research Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dndi-template-research-collaboration-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-04-20 12:31:28 [post_modified_gmt] => 2023-04-20 12:31:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9859 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [33] => WP_Post Object ( [ID] => 9090 [post_author] => 5 [post_date] => 2023-03-08 10:46:30 [post_date_gmt] => 2023-03-08 10:46:30 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:14:44 [post_modified_gmt] => 2023-03-08 11:14:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9090 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [34] => WP_Post Object ( [ID] => 9089 [post_author] => 5 [post_date] => 2023-03-08 10:34:53 [post_date_gmt] => 2023-03-08 10:34:53 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:24:52 [post_modified_gmt] => 2023-03-08 11:24:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9089 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [35] => WP_Post Object ( [ID] => 9088 [post_author] => 5 [post_date] => 2023-03-08 10:31:00 [post_date_gmt] => 2023-03-08 10:31:00 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-03-08 10:31:00 [post_modified_gmt] => 2023-03-08 10:31:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9088 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [36] => WP_Post Object ( [ID] => 9087 [post_author] => 5 [post_date] => 2023-03-08 10:15:07 [post_date_gmt] => 2023-03-08 10:15:07 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-03-08 10:15:07 [post_modified_gmt] => 2023-03-08 10:15:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9087 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [37] => WP_Post Object ( [ID] => 9086 [post_author] => 5 [post_date] => 2023-03-08 09:59:11 [post_date_gmt] => 2023-03-08 09:59:11 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:16:01 [post_modified_gmt] => 2023-03-08 12:16:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9086 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [38] => WP_Post Object ( [ID] => 9083 [post_author] => 5 [post_date] => 2023-03-08 09:45:42 [post_date_gmt] => 2023-03-08 09:45:42 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:15:35 [post_modified_gmt] => 2023-03-08 11:15:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9083 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [39] => WP_Post Object ( [ID] => 9082 [post_author] => 5 [post_date] => 2023-03-08 09:34:23 [post_date_gmt] => 2023-03-08 09:34:23 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:17:32 [post_modified_gmt] => 2023-03-08 11:17:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9082 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [40] => WP_Post Object ( [ID] => 9081 [post_author] => 5 [post_date] => 2023-03-07 14:59:57 [post_date_gmt] => 2023-03-07 14:59:57 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:19:49 [post_modified_gmt] => 2023-03-08 11:19:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9081 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [41] => WP_Post Object ( [ID] => 9080 [post_author] => 5 [post_date] => 2023-03-07 14:44:45 [post_date_gmt] => 2023-03-07 14:44:45 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:20:27 [post_modified_gmt] => 2023-03-08 11:20:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9080 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [42] => WP_Post Object ( [ID] => 9079 [post_author] => 5 [post_date] => 2023-03-07 14:40:00 [post_date_gmt] => 2023-03-07 14:40:00 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:33:10 [post_modified_gmt] => 2023-05-01 14:33:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9079 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [43] => WP_Post Object ( [ID] => 9078 [post_author] => 5 [post_date] => 2023-03-07 14:31:51 [post_date_gmt] => 2023-03-07 14:31:51 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:23:22 [post_modified_gmt] => 2023-03-08 11:23:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9078 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [44] => WP_Post Object ( [ID] => 9077 [post_author] => 5 [post_date] => 2023-03-07 14:28:57 [post_date_gmt] => 2023-03-07 14:28:57 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:21:30 [post_modified_gmt] => 2023-03-08 11:21:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9077 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [45] => WP_Post Object ( [ID] => 9076 [post_author] => 5 [post_date] => 2023-03-07 14:09:37 [post_date_gmt] => 2023-03-07 14:09:37 [post_content] => [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:22:36 [post_modified_gmt] => 2023-03-08 11:22:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9076 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [46] => WP_Post Object ( [ID] => 9073 [post_author] => 5 [post_date] => 2023-03-07 12:46:52 [post_date_gmt] => 2023-03-07 12:46:52 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:18:23 [post_modified_gmt] => 2023-03-08 12:18:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9073 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [47] => WP_Post Object ( [ID] => 9072 [post_author] => 5 [post_date] => 2023-03-07 12:24:17 [post_date_gmt] => 2023-03-07 12:24:17 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:19:29 [post_modified_gmt] => 2023-03-08 12:19:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9072 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [48] => WP_Post Object ( [ID] => 9071 [post_author] => 5 [post_date] => 2023-03-07 12:09:50 [post_date_gmt] => 2023-03-07 12:09:50 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:16:59 [post_modified_gmt] => 2023-03-08 12:16:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9071 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [49] => WP_Post Object ( [ID] => 9070 [post_author] => 5 [post_date] => 2023-03-06 18:39:51 [post_date_gmt] => 2023-03-06 18:39:51 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:16:23 [post_modified_gmt] => 2023-03-08 12:16:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9070 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [50] => WP_Post Object ( [ID] => 9069 [post_author] => 5 [post_date] => 2023-03-06 18:34:47 [post_date_gmt] => 2023-03-06 18:34:47 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:15:26 [post_modified_gmt] => 2023-03-08 12:15:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9069 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [51] => WP_Post Object ( [ID] => 9068 [post_author] => 5 [post_date] => 2023-03-06 18:20:18 [post_date_gmt] => 2023-03-06 18:20:18 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:35:08 [post_modified_gmt] => 2023-03-08 11:35:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9068 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [52] => WP_Post Object ( [ID] => 9067 [post_author] => 5 [post_date] => 2023-03-06 16:40:37 [post_date_gmt] => 2023-03-06 16:40:37 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:36:48 [post_modified_gmt] => 2023-03-08 11:36:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9067 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [53] => WP_Post Object ( [ID] => 9066 [post_author] => 5 [post_date] => 2023-03-06 15:55:39 [post_date_gmt] => 2023-03-06 15:55:39 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:38:10 [post_modified_gmt] => 2023-03-08 11:38:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9066 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [54] => WP_Post Object ( [ID] => 9065 [post_author] => 5 [post_date] => 2023-03-06 15:36:15 [post_date_gmt] => 2023-03-06 15:36:15 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:13:07 [post_modified_gmt] => 2023-03-08 12:13:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9065 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [55] => WP_Post Object ( [ID] => 9064 [post_author] => 5 [post_date] => 2023-03-06 15:24:23 [post_date_gmt] => 2023-03-06 15:24:23 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:32:16 [post_modified_gmt] => 2023-05-01 14:32:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9064 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [56] => WP_Post Object ( [ID] => 9063 [post_author] => 5 [post_date] => 2023-03-06 15:10:08 [post_date_gmt] => 2023-03-06 15:10:08 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:14:56 [post_modified_gmt] => 2023-03-08 12:14:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9063 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [57] => WP_Post Object ( [ID] => 9062 [post_author] => 5 [post_date] => 2023-03-06 15:05:13 [post_date_gmt] => 2023-03-06 15:05:13 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-03-08 11:33:55 [post_modified_gmt] => 2023-03-08 11:33:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9062 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [58] => WP_Post Object ( [ID] => 9061 [post_author] => 5 [post_date] => 2023-03-06 13:14:19 [post_date_gmt] => 2023-03-06 13:14:19 [post_content] => [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:14:30 [post_modified_gmt] => 2023-03-08 12:14:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9061 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [59] => WP_Post Object ( [ID] => 9057 [post_author] => 5 [post_date] => 2023-03-06 10:34:15 [post_date_gmt] => 2023-03-06 10:34:15 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-03-06 10:34:15 [post_modified_gmt] => 2023-03-06 10:34:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9057 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [60] => WP_Post Object ( [ID] => 9056 [post_author] => 5 [post_date] => 2023-03-06 09:37:28 [post_date_gmt] => 2023-03-06 09:37:28 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:32:43 [post_modified_gmt] => 2023-03-08 12:32:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9056 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [61] => WP_Post Object ( [ID] => 9055 [post_author] => 5 [post_date] => 2023-03-03 16:02:36 [post_date_gmt] => 2023-03-03 16:02:36 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-03-03 16:03:15 [post_modified_gmt] => 2023-03-03 16:03:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9055 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [62] => WP_Post Object ( [ID] => 9054 [post_author] => 5 [post_date] => 2023-03-03 15:46:50 [post_date_gmt] => 2023-03-03 15:46:50 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:33:38 [post_modified_gmt] => 2023-03-08 12:33:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9054 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [63] => WP_Post Object ( [ID] => 9053 [post_author] => 5 [post_date] => 2023-03-03 15:34:51 [post_date_gmt] => 2023-03-03 15:34:51 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:31:52 [post_modified_gmt] => 2023-03-08 12:31:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9053 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [64] => WP_Post Object ( [ID] => 9052 [post_author] => 5 [post_date] => 2023-03-03 15:20:20 [post_date_gmt] => 2023-03-03 15:20:20 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-03-03 15:21:32 [post_modified_gmt] => 2023-03-03 15:21:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9052 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [65] => WP_Post Object ( [ID] => 9051 [post_author] => 5 [post_date] => 2023-03-03 15:03:06 [post_date_gmt] => 2023-03-03 15:03:06 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-03 15:03:32 [post_modified_gmt] => 2023-03-03 15:03:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9051 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [66] => WP_Post Object ( [ID] => 9050 [post_author] => 5 [post_date] => 2023-03-03 14:35:41 [post_date_gmt] => 2023-03-03 14:35:41 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-03-06 09:50:51 [post_modified_gmt] => 2023-03-06 09:50:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9050 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [67] => WP_Post Object ( [ID] => 9049 [post_author] => 5 [post_date] => 2023-03-03 14:27:14 [post_date_gmt] => 2023-03-03 14:27:14 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:27:26 [post_modified_gmt] => 2023-03-08 12:27:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9049 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [68] => WP_Post Object ( [ID] => 9048 [post_author] => 5 [post_date] => 2023-03-03 14:14:36 [post_date_gmt] => 2023-03-03 14:14:36 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:25:46 [post_modified_gmt] => 2023-03-08 12:25:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9048 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [69] => WP_Post Object ( [ID] => 9047 [post_author] => 5 [post_date] => 2023-03-03 13:52:18 [post_date_gmt] => 2023-03-03 13:52:18 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:18:10 [post_modified_gmt] => 2023-04-28 13:18:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9047 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [70] => WP_Post Object ( [ID] => 9036 [post_author] => 5 [post_date] => 2023-03-03 13:07:34 [post_date_gmt] => 2023-03-03 13:07:34 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-03-06 10:27:24 [post_modified_gmt] => 2023-03-06 10:27:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9036 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [71] => WP_Post Object ( [ID] => 9035 [post_author] => 5 [post_date] => 2023-03-03 12:50:57 [post_date_gmt] => 2023-03-03 12:50:57 [post_content] => [post_title] => BIND Biosciences, Inc. – Yale University, Cancer Therapeutic, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bind-biosciences-inc-yale-university-cancer-therapeutic-exclusive-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-03-08 12:30:23 [post_modified_gmt] => 2023-03-08 12:30:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9035 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [72] => WP_Post Object ( [ID] => 9028 [post_author] => 5 [post_date] => 2023-03-02 16:28:59 [post_date_gmt] => 2023-03-02 16:28:59 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-03-02 16:28:59 [post_modified_gmt] => 2023-03-02 16:28:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9028 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [73] => WP_Post Object ( [ID] => 9027 [post_author] => 5 [post_date] => 2023-03-02 15:39:38 [post_date_gmt] => 2023-03-02 15:39:38 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-03-08 13:58:36 [post_modified_gmt] => 2023-03-08 13:58:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9027 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [74] => WP_Post Object ( [ID] => 9026 [post_author] => 5 [post_date] => 2023-03-02 15:24:55 [post_date_gmt] => 2023-03-02 15:24:55 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-03-08 13:55:49 [post_modified_gmt] => 2023-03-08 13:55:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9026 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [75] => WP_Post Object ( [ID] => 9025 [post_author] => 5 [post_date] => 2023-03-02 15:22:25 [post_date_gmt] => 2023-03-02 15:22:25 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-03-08 13:53:07 [post_modified_gmt] => 2023-03-08 13:53:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9025 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [76] => WP_Post Object ( [ID] => 9024 [post_author] => 5 [post_date] => 2023-03-02 15:12:45 [post_date_gmt] => 2023-03-02 15:12:45 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-03-02 15:12:45 [post_modified_gmt] => 2023-03-02 15:12:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9024 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [77] => WP_Post Object ( [ID] => 9023 [post_author] => 5 [post_date] => 2023-03-02 15:10:54 [post_date_gmt] => 2023-03-02 15:10:54 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-03-08 13:50:59 [post_modified_gmt] => 2023-03-08 13:50:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9023 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [78] => WP_Post Object ( [ID] => 9022 [post_author] => 5 [post_date] => 2023-03-02 14:32:35 [post_date_gmt] => 2023-03-02 14:32:35 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-02 14:32:35 [post_modified_gmt] => 2023-03-02 14:32:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9022 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [79] => WP_Post Object ( [ID] => 9021 [post_author] => 5 [post_date] => 2023-03-02 14:28:40 [post_date_gmt] => 2023-03-02 14:28:40 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-03-08 13:39:35 [post_modified_gmt] => 2023-03-08 13:39:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9021 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [80] => WP_Post Object ( [ID] => 9016 [post_author] => 5 [post_date] => 2023-03-02 12:51:13 [post_date_gmt] => 2023-03-02 12:51:13 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-03-08 13:46:25 [post_modified_gmt] => 2023-03-08 13:46:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9016 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [81] => WP_Post Object ( [ID] => 9015 [post_author] => 5 [post_date] => 2023-03-02 12:13:42 [post_date_gmt] => 2023-03-02 12:13:42 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-03-02 12:13:42 [post_modified_gmt] => 2023-03-02 12:13:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9015 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [82] => WP_Post Object ( [ID] => 9014 [post_author] => 5 [post_date] => 2023-03-02 10:46:18 [post_date_gmt] => 2023-03-02 10:46:18 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-03-08 13:32:58 [post_modified_gmt] => 2023-03-08 13:32:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9014 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [83] => WP_Post Object ( [ID] => 9013 [post_author] => 5 [post_date] => 2023-03-02 09:48:35 [post_date_gmt] => 2023-03-02 09:48:35 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-03-02 10:17:18 [post_modified_gmt] => 2023-03-02 10:17:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9013 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [84] => WP_Post Object ( [ID] => 9012 [post_author] => 5 [post_date] => 2023-03-02 08:44:27 [post_date_gmt] => 2023-03-02 08:44:27 [post_content] => [post_title] => National Health Service (NHS) – Pfizer/Shionogi, Antibiotic Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => national-health-service-nhs-pfizer-shionogi-antibiotic-supply-agreement [to_ping] => [pinged] => [post_modified] => 2023-03-02 10:18:58 [post_modified_gmt] => 2023-03-02 10:18:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=9012 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [85] => WP_Post Object ( [ID] => 8491 [post_author] => 5 [post_date] => 2023-01-19 11:34:54 [post_date_gmt] => 2023-01-19 11:34:54 [post_content] => [post_title] => CEPI CfP3i Vaccine Funding Agreement Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-vaccine-funding-agreement-template [to_ping] => [pinged] => [post_modified] => 2023-01-19 11:34:54 [post_modified_gmt] => 2023-01-19 11:34:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8491 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [86] => WP_Post Object ( [ID] => 8490 [post_author] => 5 [post_date] => 2023-01-19 11:11:46 [post_date_gmt] => 2023-01-19 11:11:46 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-04-04 16:07:40 [post_modified_gmt] => 2023-04-04 16:07:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8490 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [87] => WP_Post Object ( [ID] => 8489 [post_author] => 5 [post_date] => 2023-01-19 10:44:52 [post_date_gmt] => 2023-01-19 10:44:52 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-01-19 10:44:52 [post_modified_gmt] => 2023-01-19 10:44:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8489 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [88] => WP_Post Object ( [ID] => 8488 [post_author] => 5 [post_date] => 2023-01-19 10:15:15 [post_date_gmt] => 2023-01-19 10:15:15 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-01-19 10:15:15 [post_modified_gmt] => 2023-01-19 10:15:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8488 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [89] => WP_Post Object ( [ID] => 8487 [post_author] => 5 [post_date] => 2023-01-19 09:59:54 [post_date_gmt] => 2023-01-19 09:59:54 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-03-30 14:47:25 [post_modified_gmt] => 2023-03-30 14:47:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8487 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [90] => WP_Post Object ( [ID] => 8486 [post_author] => 5 [post_date] => 2023-01-19 09:46:36 [post_date_gmt] => 2023-01-19 09:46:36 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:46:36 [post_modified_gmt] => 2023-01-19 09:46:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8486 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [91] => WP_Post Object ( [ID] => 8485 [post_author] => 5 [post_date] => 2023-01-19 09:39:38 [post_date_gmt] => 2023-01-19 09:39:38 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:39:38 [post_modified_gmt] => 2023-01-19 09:39:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8485 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [92] => WP_Post Object ( [ID] => 8484 [post_author] => 5 [post_date] => 2023-01-19 09:17:50 [post_date_gmt] => 2023-01-19 09:17:50 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20 [to_ping] => [pinged] => [post_modified] => 2023-01-19 09:17:50 [post_modified_gmt] => 2023-01-19 09:17:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8484 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [93] => WP_Post Object ( [ID] => 8482 [post_author] => 5 [post_date] => 2023-01-18 16:32:52 [post_date_gmt] => 2023-01-18 16:32:52 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-18 16:32:52 [post_modified_gmt] => 2023-01-18 16:32:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8482 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [94] => WP_Post Object ( [ID] => 8481 [post_author] => 5 [post_date] => 2023-01-18 15:49:38 [post_date_gmt] => 2023-01-18 15:49:38 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-19 12:07:24 [post_modified_gmt] => 2023-01-19 12:07:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8481 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [95] => WP_Post Object ( [ID] => 8480 [post_author] => 5 [post_date] => 2023-01-17 17:53:00 [post_date_gmt] => 2023-01-17 17:53:00 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:53:00 [post_modified_gmt] => 2023-01-17 17:53:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8480 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [96] => WP_Post Object ( [ID] => 8479 [post_author] => 5 [post_date] => 2023-01-17 17:35:45 [post_date_gmt] => 2023-01-17 17:35:45 [post_content] => [post_title] => CEPI CfP3i Template Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-cfp3i-template-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-17 17:35:45 [post_modified_gmt] => 2023-01-17 17:35:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8479 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [97] => WP_Post Object ( [ID] => 8469 [post_author] => 5 [post_date] => 2023-01-13 13:35:47 [post_date_gmt] => 2023-01-13 13:35:47 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19 [to_ping] => [pinged] => [post_modified] => 2023-01-13 13:35:47 [post_modified_gmt] => 2023-01-13 13:35:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8469 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [98] => WP_Post Object ( [ID] => 8468 [post_author] => 5 [post_date] => 2023-01-11 14:35:38 [post_date_gmt] => 2023-01-11 14:35:38 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-03-31 10:46:55 [post_modified_gmt] => 2023-03-31 10:46:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8468 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [99] => WP_Post Object ( [ID] => 8467 [post_author] => 5 [post_date] => 2023-01-11 14:29:13 [post_date_gmt] => 2023-01-11 14:29:13 [post_content] => [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-11 14:36:41 [post_modified_gmt] => 2023-01-11 14:36:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8467 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [100] => WP_Post Object ( [ID] => 8462 [post_author] => 5 [post_date] => 2023-01-10 12:12:52 [post_date_gmt] => 2023-01-10 12:12:52 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-03-29 08:30:22 [post_modified_gmt] => 2023-03-29 08:30:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8462 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [101] => WP_Post Object ( [ID] => 8461 [post_author] => 5 [post_date] => 2023-01-10 09:08:41 [post_date_gmt] => 2023-01-10 09:08:41 [post_content] => [post_title] => CEPI - CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-10 09:17:07 [post_modified_gmt] => 2023-01-10 09:17:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8461 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [102] => WP_Post Object ( [ID] => 8460 [post_author] => 5 [post_date] => 2023-01-05 12:38:47 [post_date_gmt] => 2023-01-05 12:38:47 [post_content] => [post_title] => AUTM Preliminary Patent Management Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => autm-preliminary-patent-management-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-05 12:39:08 [post_modified_gmt] => 2023-01-05 12:39:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8460 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [103] => WP_Post Object ( [ID] => 8459 [post_author] => 5 [post_date] => 2023-01-05 12:24:50 [post_date_gmt] => 2023-01-05 12:24:50 [post_content] => [post_title] => AUTM Preliminary Patent Management Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => autm-preliminary-patent-management-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-01-05 12:24:50 [post_modified_gmt] => 2023-01-05 12:24:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8459 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [104] => WP_Post Object ( [ID] => 8458 [post_author] => 5 [post_date] => 2023-01-05 12:18:04 [post_date_gmt] => 2023-01-05 12:18:04 [post_content] => [post_title] => AUTM Preliminary Patent Management Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => autm-preliminary-patent-management-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-05 12:18:04 [post_modified_gmt] => 2023-01-05 12:18:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8458 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [105] => WP_Post Object ( [ID] => 8457 [post_author] => 5 [post_date] => 2023-01-05 12:07:10 [post_date_gmt] => 2023-01-05 12:07:10 [post_content] => [post_title] => AUTM Preliminary Patent Management Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => autm-preliminary-patent-management-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:15:18 [post_modified_gmt] => 2023-04-28 13:15:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8457 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [106] => WP_Post Object ( [ID] => 8456 [post_author] => 5 [post_date] => 2023-01-05 11:54:22 [post_date_gmt] => 2023-01-05 11:54:22 [post_content] => [post_title] => AUTM Preliminary Patent Management Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => autm-preliminary-patent-management-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:14:46 [post_modified_gmt] => 2023-04-28 13:14:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8456 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [107] => WP_Post Object ( [ID] => 8447 [post_author] => 5 [post_date] => 2022-12-15 15:33:22 [post_date_gmt] => 2022-12-15 15:33:22 [post_content] => [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-government-ology-bioservices-covid-19-plasmid-procurement-agreement [to_ping] => [pinged] => [post_modified] => 2022-12-15 15:33:22 [post_modified_gmt] => 2022-12-15 15:33:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8447 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [108] => WP_Post Object ( [ID] => 3910 [post_author] => 5 [post_date] => 2022-12-15 14:44:16 [post_date_gmt] => 2022-12-15 14:44:16 [post_content] => [post_title] => Merck – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-21 15:31:00 [post_modified_gmt] => 2023-04-21 15:31:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3910 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [109] => WP_Post Object ( [ID] => 5625 [post_author] => 5 [post_date] => 2022-12-15 09:51:55 [post_date_gmt] => 2022-12-15 09:51:55 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-12-15 09:51:55 [post_modified_gmt] => 2022-12-15 09:51:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5625 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [110] => WP_Post Object ( [ID] => 8314 [post_author] => 5 [post_date] => 2022-12-13 11:46:36 [post_date_gmt] => 2022-12-13 11:46:36 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-04-27 13:02:14 [post_modified_gmt] => 2023-04-27 13:02:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8314 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [111] => WP_Post Object ( [ID] => 8313 [post_author] => 5 [post_date] => 2022-12-13 10:48:56 [post_date_gmt] => 2022-12-13 10:48:56 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-12-13 10:48:56 [post_modified_gmt] => 2022-12-13 10:48:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8313 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [112] => WP_Post Object ( [ID] => 8312 [post_author] => 5 [post_date] => 2022-12-13 10:35:08 [post_date_gmt] => 2022-12-13 10:35:08 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-03-30 14:46:26 [post_modified_gmt] => 2023-03-30 14:46:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8312 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [113] => WP_Post Object ( [ID] => 8311 [post_author] => 5 [post_date] => 2022-12-13 10:09:44 [post_date_gmt] => 2022-12-13 10:09:44 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-03-30 14:43:46 [post_modified_gmt] => 2023-03-30 14:43:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8311 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [114] => WP_Post Object ( [ID] => 8192 [post_author] => 5 [post_date] => 2022-12-13 09:04:26 [post_date_gmt] => 2022-12-13 09:04:26 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-12-13 09:05:52 [post_modified_gmt] => 2022-12-13 09:05:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8192 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [115] => WP_Post Object ( [ID] => 8191 [post_author] => 5 [post_date] => 2022-12-12 16:19:19 [post_date_gmt] => 2022-12-12 16:19:19 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:55:07 [post_modified_gmt] => 2022-12-13 12:55:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8191 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [116] => WP_Post Object ( [ID] => 8190 [post_author] => 5 [post_date] => 2022-12-12 15:29:46 [post_date_gmt] => 2022-12-12 15:29:46 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-12-14 13:05:30 [post_modified_gmt] => 2022-12-14 13:05:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8190 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [117] => WP_Post Object ( [ID] => 8157 [post_author] => 5 [post_date] => 2022-12-12 15:23:50 [post_date_gmt] => 2022-12-12 15:23:50 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-04-04 16:01:23 [post_modified_gmt] => 2023-04-04 16:01:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8157 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [118] => WP_Post Object ( [ID] => 8152 [post_author] => 5 [post_date] => 2022-12-12 12:04:21 [post_date_gmt] => 2022-12-12 12:04:21 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:56:37 [post_modified_gmt] => 2022-12-13 12:56:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8152 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [119] => WP_Post Object ( [ID] => 8151 [post_author] => 5 [post_date] => 2022-12-12 11:56:08 [post_date_gmt] => 2022-12-12 11:56:08 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-04-04 16:02:18 [post_modified_gmt] => 2023-04-04 16:02:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8151 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [120] => WP_Post Object ( [ID] => 8150 [post_author] => 5 [post_date] => 2022-12-12 11:21:26 [post_date_gmt] => 2022-12-12 11:21:26 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-12-12 11:48:09 [post_modified_gmt] => 2022-12-12 11:48:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8150 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [121] => WP_Post Object ( [ID] => 8143 [post_author] => 5 [post_date] => 2022-12-12 11:10:19 [post_date_gmt] => 2022-12-12 11:10:19 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-12-12 11:10:19 [post_modified_gmt] => 2022-12-12 11:10:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8143 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [122] => WP_Post Object ( [ID] => 8142 [post_author] => 5 [post_date] => 2022-12-12 10:40:31 [post_date_gmt] => 2022-12-12 10:40:31 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-12-13 12:57:50 [post_modified_gmt] => 2022-12-13 12:57:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8142 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [123] => WP_Post Object ( [ID] => 8131 [post_author] => 5 [post_date] => 2022-12-12 09:57:36 [post_date_gmt] => 2022-12-12 09:57:36 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:38:50 [post_modified_gmt] => 2023-04-28 13:38:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8131 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [124] => WP_Post Object ( [ID] => 8130 [post_author] => 5 [post_date] => 2022-12-12 09:34:49 [post_date_gmt] => 2022-12-12 09:34:49 [post_content] => [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-03-30 14:45:50 [post_modified_gmt] => 2023-03-30 14:45:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8130 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [125] => WP_Post Object ( [ID] => 8129 [post_author] => 5 [post_date] => 2022-12-12 08:55:53 [post_date_gmt] => 2022-12-12 08:55:53 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-05-05 13:48:02 [post_modified_gmt] => 2023-05-05 13:48:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8129 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [126] => WP_Post Object ( [ID] => 8051 [post_author] => 5 [post_date] => 2022-12-12 08:39:19 [post_date_gmt] => 2022-12-12 08:39:19 [post_content] => [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:54:45 [post_modified_gmt] => 2023-01-10 13:54:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=8051 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [127] => WP_Post Object ( [ID] => 7582 [post_author] => 5 [post_date] => 2022-12-08 08:48:17 [post_date_gmt] => 2022-12-08 08:48:17 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions-9 [to_ping] => [pinged] => [post_modified] => 2022-12-08 08:48:17 [post_modified_gmt] => 2022-12-08 08:48:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7582 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [128] => WP_Post Object ( [ID] => 7581 [post_author] => 5 [post_date] => 2022-12-08 08:20:09 [post_date_gmt] => 2022-12-08 08:20:09 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions-8 [to_ping] => [pinged] => [post_modified] => 2022-12-08 08:20:09 [post_modified_gmt] => 2022-12-08 08:20:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7581 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [129] => WP_Post Object ( [ID] => 7580 [post_author] => 5 [post_date] => 2022-12-08 08:14:21 [post_date_gmt] => 2022-12-08 08:14:21 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions-7 [to_ping] => [pinged] => [post_modified] => 2022-12-08 08:14:21 [post_modified_gmt] => 2022-12-08 08:14:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7580 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [130] => WP_Post Object ( [ID] => 7570 [post_author] => 5 [post_date] => 2022-12-07 16:44:09 [post_date_gmt] => 2022-12-07 16:44:09 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions-6 [to_ping] => [pinged] => [post_modified] => 2022-12-07 16:44:09 [post_modified_gmt] => 2022-12-07 16:44:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7570 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [131] => WP_Post Object ( [ID] => 7569 [post_author] => 5 [post_date] => 2022-12-07 16:39:11 [post_date_gmt] => 2022-12-07 16:39:11 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions-5 [to_ping] => [pinged] => [post_modified] => 2022-12-07 16:39:11 [post_modified_gmt] => 2022-12-07 16:39:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7569 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [132] => WP_Post Object ( [ID] => 7568 [post_author] => 5 [post_date] => 2022-12-07 16:18:53 [post_date_gmt] => 2022-12-07 16:18:53 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions-4 [to_ping] => [pinged] => [post_modified] => 2022-12-07 16:18:53 [post_modified_gmt] => 2022-12-07 16:18:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7568 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [133] => WP_Post Object ( [ID] => 7567 [post_author] => 5 [post_date] => 2022-12-07 16:14:54 [post_date_gmt] => 2022-12-07 16:14:54 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions-3 [to_ping] => [pinged] => [post_modified] => 2023-04-27 12:35:43 [post_modified_gmt] => 2023-04-27 12:35:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7567 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [134] => WP_Post Object ( [ID] => 7563 [post_author] => 5 [post_date] => 2022-12-07 16:00:00 [post_date_gmt] => 2022-12-07 16:00:00 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions-2 [to_ping] => [pinged] => [post_modified] => 2023-03-21 09:17:44 [post_modified_gmt] => 2023-03-21 09:17:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7563 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [135] => WP_Post Object ( [ID] => 7562 [post_author] => 5 [post_date] => 2022-12-07 15:26:44 [post_date_gmt] => 2022-12-07 15:26:44 [post_content] => [post_title] => FIND Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => find-sample-funding-terms-and-conditions [to_ping] => [pinged] => [post_modified] => 2023-03-29 08:14:29 [post_modified_gmt] => 2023-03-29 08:14:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7562 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [136] => WP_Post Object ( [ID] => 7468 [post_author] => 5 [post_date] => 2022-12-05 12:56:35 [post_date_gmt] => 2022-12-05 12:56:35 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-10 [to_ping] => [pinged] => [post_modified] => 2022-12-05 12:56:35 [post_modified_gmt] => 2022-12-05 12:56:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7468 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [137] => WP_Post Object ( [ID] => 7467 [post_author] => 5 [post_date] => 2022-12-05 12:50:39 [post_date_gmt] => 2022-12-05 12:50:39 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-9 [to_ping] => [pinged] => [post_modified] => 2022-12-05 12:50:39 [post_modified_gmt] => 2022-12-05 12:50:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7467 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [138] => WP_Post Object ( [ID] => 7466 [post_author] => 5 [post_date] => 2022-12-05 12:39:45 [post_date_gmt] => 2022-12-05 12:39:45 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-8 [to_ping] => [pinged] => [post_modified] => 2022-12-05 12:39:45 [post_modified_gmt] => 2022-12-05 12:39:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7466 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [139] => WP_Post Object ( [ID] => 7464 [post_author] => 5 [post_date] => 2022-12-05 11:38:57 [post_date_gmt] => 2022-12-05 11:38:57 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-7 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:46:46 [post_modified_gmt] => 2023-04-27 11:46:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7464 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [140] => WP_Post Object ( [ID] => 7445 [post_author] => 5 [post_date] => 2022-12-05 11:10:08 [post_date_gmt] => 2022-12-05 11:10:08 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-6 [to_ping] => [pinged] => [post_modified] => 2022-12-05 11:10:08 [post_modified_gmt] => 2022-12-05 11:10:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7445 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [141] => WP_Post Object ( [ID] => 7463 [post_author] => 5 [post_date] => 2022-12-05 10:28:51 [post_date_gmt] => 2022-12-05 10:28:51 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-5 [to_ping] => [pinged] => [post_modified] => 2022-12-05 10:28:51 [post_modified_gmt] => 2022-12-05 10:28:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7463 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [142] => WP_Post Object ( [ID] => 7462 [post_author] => 5 [post_date] => 2022-12-05 10:15:17 [post_date_gmt] => 2022-12-05 10:15:17 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-4 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:20:59 [post_modified_gmt] => 2023-03-28 14:20:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7462 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [143] => WP_Post Object ( [ID] => 7444 [post_author] => 5 [post_date] => 2022-12-01 14:17:31 [post_date_gmt] => 2022-12-01 14:17:31 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-3 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:45:56 [post_modified_gmt] => 2023-04-27 11:45:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7444 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [144] => WP_Post Object ( [ID] => 7443 [post_author] => 5 [post_date] => 2022-12-01 11:47:54 [post_date_gmt] => 2022-12-01 11:47:54 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions-2 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:44:53 [post_modified_gmt] => 2023-04-27 11:44:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7443 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [145] => WP_Post Object ( [ID] => 7442 [post_author] => 5 [post_date] => 2022-12-01 11:26:45 [post_date_gmt] => 2022-12-01 11:26:45 [post_content] => [post_title] => UnitaidExplore Sample Funding Terms and Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => unitaidexplore-sample-funding-terms-and-conditions [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:44:13 [post_modified_gmt] => 2023-04-27 11:44:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=7442 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [146] => WP_Post Object ( [ID] => 6638 [post_author] => 5 [post_date] => 2022-11-09 13:48:21 [post_date_gmt] => 2022-11-09 13:48:21 [post_content] => [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-11-09 13:49:21 [post_modified_gmt] => 2022-11-09 13:49:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6638 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [147] => WP_Post Object ( [ID] => 6637 [post_author] => 5 [post_date] => 2022-11-09 13:40:00 [post_date_gmt] => 2022-11-09 13:40:00 [post_content] => [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-11-09 13:40:00 [post_modified_gmt] => 2022-11-09 13:40:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6637 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [148] => WP_Post Object ( [ID] => 6636 [post_author] => 5 [post_date] => 2022-11-09 13:21:22 [post_date_gmt] => 2022-11-09 13:21:22 [post_content] => [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-05-17 11:45:37 [post_modified_gmt] => 2023-05-17 11:45:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6636 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [149] => WP_Post Object ( [ID] => 6635 [post_author] => 5 [post_date] => 2022-11-09 13:05:41 [post_date_gmt] => 2022-11-09 13:05:41 [post_content] => [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-04-27 13:17:56 [post_modified_gmt] => 2023-04-27 13:17:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6635 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [150] => WP_Post Object ( [ID] => 6634 [post_author] => 5 [post_date] => 2022-11-08 19:23:52 [post_date_gmt] => 2022-11-08 19:23:52 [post_content] => [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-04-21 15:26:58 [post_modified_gmt] => 2023-04-21 15:26:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6634 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [151] => WP_Post Object ( [ID] => 6633 [post_author] => 5 [post_date] => 2022-11-08 19:03:56 [post_date_gmt] => 2022-11-08 19:03:56 [post_content] => [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-04-27 13:21:42 [post_modified_gmt] => 2023-04-27 13:21:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6633 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [152] => WP_Post Object ( [ID] => 6632 [post_author] => 5 [post_date] => 2022-11-08 18:14:54 [post_date_gmt] => 2022-11-08 18:14:54 [post_content] => [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-04-21 15:24:52 [post_modified_gmt] => 2023-04-21 15:24:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6632 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [153] => WP_Post Object ( [ID] => 6631 [post_author] => 5 [post_date] => 2022-11-08 16:07:28 [post_date_gmt] => 2022-11-08 16:07:28 [post_content] => [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-27 13:19:40 [post_modified_gmt] => 2023-04-27 13:19:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6631 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [154] => WP_Post Object ( [ID] => 6630 [post_author] => 5 [post_date] => 2022-11-08 15:22:11 [post_date_gmt] => 2022-11-08 15:22:11 [post_content] => [post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-21 15:25:42 [post_modified_gmt] => 2023-04-21 15:25:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6630 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [155] => WP_Post Object ( [ID] => 6629 [post_author] => 5 [post_date] => 2022-11-08 14:54:13 [post_date_gmt] => 2022-11-08 14:54:13 [post_content] => [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-11-08 14:54:13 [post_modified_gmt] => 2022-11-08 14:54:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6629 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [156] => WP_Post Object ( [ID] => 6628 [post_author] => 5 [post_date] => 2022-11-08 13:12:06 [post_date_gmt] => 2022-11-08 13:12:06 [post_content] => [post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-27 13:17:23 [post_modified_gmt] => 2023-04-27 13:17:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6628 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [157] => WP_Post Object ( [ID] => 6333 [post_author] => 5 [post_date] => 2022-10-27 15:17:29 [post_date_gmt] => 2022-10-27 15:17:29 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:49:25 [post_modified_gmt] => 2023-05-08 13:49:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6333 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [158] => WP_Post Object ( [ID] => 6332 [post_author] => 5 [post_date] => 2022-10-27 15:11:17 [post_date_gmt] => 2022-10-27 15:11:17 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:49:33 [post_modified_gmt] => 2023-05-08 13:49:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6332 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [159] => WP_Post Object ( [ID] => 6330 [post_author] => 5 [post_date] => 2022-10-27 15:05:13 [post_date_gmt] => 2022-10-27 15:05:13 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:49:43 [post_modified_gmt] => 2023-05-08 13:49:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6330 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [160] => WP_Post Object ( [ID] => 6329 [post_author] => 5 [post_date] => 2022-10-27 11:59:35 [post_date_gmt] => 2022-10-27 11:59:35 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:49:50 [post_modified_gmt] => 2023-05-08 13:49:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6329 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [161] => WP_Post Object ( [ID] => 6328 [post_author] => 5 [post_date] => 2022-10-27 11:49:09 [post_date_gmt] => 2022-10-27 11:49:09 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:49:57 [post_modified_gmt] => 2023-05-08 13:49:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6328 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [162] => WP_Post Object ( [ID] => 6327 [post_author] => 5 [post_date] => 2022-10-27 11:45:45 [post_date_gmt] => 2022-10-27 11:45:45 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:50:05 [post_modified_gmt] => 2023-05-08 13:50:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6327 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [163] => WP_Post Object ( [ID] => 6326 [post_author] => 5 [post_date] => 2022-10-27 11:13:28 [post_date_gmt] => 2022-10-27 11:13:28 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-05-17 10:00:21 [post_modified_gmt] => 2023-05-17 10:00:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6326 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [164] => WP_Post Object ( [ID] => 6325 [post_author] => 5 [post_date] => 2022-10-27 10:57:10 [post_date_gmt] => 2022-10-27 10:57:10 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:50:19 [post_modified_gmt] => 2023-05-08 13:50:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6325 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [165] => WP_Post Object ( [ID] => 6324 [post_author] => 5 [post_date] => 2022-10-27 10:23:50 [post_date_gmt] => 2022-10-27 10:23:50 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:50:28 [post_modified_gmt] => 2023-05-08 13:50:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6324 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [166] => WP_Post Object ( [ID] => 6323 [post_author] => 5 [post_date] => 2022-10-27 09:37:11 [post_date_gmt] => 2022-10-27 09:37:11 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:50:34 [post_modified_gmt] => 2023-05-08 13:50:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6323 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [167] => WP_Post Object ( [ID] => 6322 [post_author] => 5 [post_date] => 2022-10-27 09:13:33 [post_date_gmt] => 2022-10-27 09:13:33 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:50:42 [post_modified_gmt] => 2023-05-08 13:50:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6322 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [168] => WP_Post Object ( [ID] => 6319 [post_author] => 5 [post_date] => 2022-10-26 13:16:20 [post_date_gmt] => 2022-10-26 13:16:20 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:50:48 [post_modified_gmt] => 2023-05-08 13:50:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6319 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [169] => WP_Post Object ( [ID] => 6318 [post_author] => 5 [post_date] => 2022-10-26 13:08:20 [post_date_gmt] => 2022-10-26 13:08:20 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:50:55 [post_modified_gmt] => 2023-05-08 13:50:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6318 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [170] => WP_Post Object ( [ID] => 6317 [post_author] => 5 [post_date] => 2022-10-26 12:22:38 [post_date_gmt] => 2022-10-26 12:22:38 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:51:05 [post_modified_gmt] => 2023-05-08 13:51:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6317 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [171] => WP_Post Object ( [ID] => 6316 [post_author] => 5 [post_date] => 2022-10-26 11:26:56 [post_date_gmt] => 2022-10-26 11:26:56 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:51:12 [post_modified_gmt] => 2023-05-08 13:51:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6316 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [172] => WP_Post Object ( [ID] => 6315 [post_author] => 5 [post_date] => 2022-10-26 10:20:15 [post_date_gmt] => 2022-10-26 10:20:15 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:51:18 [post_modified_gmt] => 2023-05-08 13:51:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6315 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [173] => WP_Post Object ( [ID] => 6314 [post_author] => 5 [post_date] => 2022-10-26 10:01:08 [post_date_gmt] => 2022-10-26 10:01:08 [post_content] => [post_title] => DNDi – BioDelivery Sciences International, Visceral Leishmaniasis Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => drugs-for-neglected-diseases-initiative-biodelivery-sciences-international-visceral-leishmaniasis-research-collaboration-agreement [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:51:25 [post_modified_gmt] => 2023-05-08 13:51:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6314 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [174] => WP_Post Object ( [ID] => 6289 [post_author] => 5 [post_date] => 2022-10-26 07:36:18 [post_date_gmt] => 2022-10-26 07:36:18 [post_content] => [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-10-26 07:36:19 [post_modified_gmt] => 2022-10-26 07:36:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6289 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [175] => WP_Post Object ( [ID] => 6288 [post_author] => 5 [post_date] => 2022-10-26 06:46:06 [post_date_gmt] => 2022-10-26 06:46:06 [post_content] => [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-10-26 06:47:52 [post_modified_gmt] => 2022-10-26 06:47:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6288 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [176] => WP_Post Object ( [ID] => 6287 [post_author] => 5 [post_date] => 2022-10-25 15:22:03 [post_date_gmt] => 2022-10-25 15:22:03 [post_content] => [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-10-25 15:22:03 [post_modified_gmt] => 2022-10-25 15:22:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6287 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [177] => WP_Post Object ( [ID] => 6286 [post_author] => 5 [post_date] => 2022-10-25 15:16:07 [post_date_gmt] => 2022-10-25 15:16:07 [post_content] => [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-10-25 15:17:06 [post_modified_gmt] => 2022-10-25 15:17:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6286 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [178] => WP_Post Object ( [ID] => 6285 [post_author] => 5 [post_date] => 2022-10-25 15:01:54 [post_date_gmt] => 2022-10-25 15:01:54 [post_content] => [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-10-25 15:01:54 [post_modified_gmt] => 2022-10-25 15:01:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6285 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [179] => WP_Post Object ( [ID] => 6284 [post_author] => 5 [post_date] => 2022-10-25 14:47:20 [post_date_gmt] => 2022-10-25 14:47:20 [post_content] => [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-10-25 14:55:56 [post_modified_gmt] => 2022-10-25 14:55:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6284 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [180] => WP_Post Object ( [ID] => 6283 [post_author] => 5 [post_date] => 2022-10-25 14:33:12 [post_date_gmt] => 2022-10-25 14:33:12 [post_content] => [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-10-26 07:43:58 [post_modified_gmt] => 2022-10-26 07:43:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6283 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [181] => WP_Post Object ( [ID] => 6282 [post_author] => 5 [post_date] => 2022-10-25 09:24:40 [post_date_gmt] => 2022-10-25 09:24:40 [post_content] => [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-10-26 07:46:59 [post_modified_gmt] => 2022-10-26 07:46:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6282 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [182] => WP_Post Object ( [ID] => 6281 [post_author] => 5 [post_date] => 2022-10-25 08:56:46 [post_date_gmt] => 2022-10-25 08:56:46 [post_content] => [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:55:54 [post_modified_gmt] => 2023-04-27 11:55:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6281 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [183] => WP_Post Object ( [ID] => 6279 [post_author] => 5 [post_date] => 2022-10-25 08:07:31 [post_date_gmt] => 2022-10-25 08:07:31 [post_content] => [post_title] => Wellcome Trust – PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-10-25 08:09:52 [post_modified_gmt] => 2022-10-25 08:09:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6279 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [184] => WP_Post Object ( [ID] => 6278 [post_author] => 5 [post_date] => 2022-10-25 07:59:13 [post_date_gmt] => 2022-10-25 07:59:13 [post_content] => [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-26 07:48:16 [post_modified_gmt] => 2022-10-26 07:48:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6278 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [185] => WP_Post Object ( [ID] => 6277 [post_author] => 5 [post_date] => 2022-10-25 07:51:55 [post_date_gmt] => 2022-10-25 07:51:55 [post_content] => [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-27 06:43:41 [post_modified_gmt] => 2023-04-27 06:43:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6277 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [186] => WP_Post Object ( [ID] => 6280 [post_author] => 5 [post_date] => 2022-10-25 07:42:19 [post_date_gmt] => 2022-10-25 07:42:19 [post_content] => [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:06:22 [post_modified_gmt] => 2023-05-08 13:06:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6280 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [187] => WP_Post Object ( [ID] => 6276 [post_author] => 5 [post_date] => 2022-10-25 07:37:13 [post_date_gmt] => 2022-10-25 07:37:13 [post_content] => [post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:55:25 [post_modified_gmt] => 2023-04-27 11:55:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=6276 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [188] => WP_Post Object ( [ID] => 5829 [post_author] => 5 [post_date] => 2022-10-11 12:04:17 [post_date_gmt] => 2022-10-11 12:04:17 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:59:01 [post_modified_gmt] => 2023-04-28 13:59:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5829 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [189] => WP_Post Object ( [ID] => 5828 [post_author] => 5 [post_date] => 2022-10-11 11:14:22 [post_date_gmt] => 2022-10-11 11:14:22 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-10-11 11:14:22 [post_modified_gmt] => 2022-10-11 11:14:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5828 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [190] => WP_Post Object ( [ID] => 5827 [post_author] => 5 [post_date] => 2022-10-11 10:21:39 [post_date_gmt] => 2022-10-11 10:21:39 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-10-11 10:21:39 [post_modified_gmt] => 2022-10-11 10:21:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5827 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [191] => WP_Post Object ( [ID] => 5814 [post_author] => 5 [post_date] => 2022-10-05 16:01:43 [post_date_gmt] => 2022-10-05 16:01:43 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-04-05 11:54:12 [post_modified_gmt] => 2023-04-05 11:54:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5814 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [192] => WP_Post Object ( [ID] => 5813 [post_author] => 5 [post_date] => 2022-10-05 15:37:35 [post_date_gmt] => 2022-10-05 15:37:35 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-04-05 11:53:33 [post_modified_gmt] => 2023-04-05 11:53:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5813 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [193] => WP_Post Object ( [ID] => 5812 [post_author] => 5 [post_date] => 2022-10-05 14:34:35 [post_date_gmt] => 2022-10-05 14:34:35 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-10-05 14:34:35 [post_modified_gmt] => 2022-10-05 14:34:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5812 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [194] => WP_Post Object ( [ID] => 5811 [post_author] => 5 [post_date] => 2022-10-05 13:31:14 [post_date_gmt] => 2022-10-05 13:31:14 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:09:25 [post_modified_gmt] => 2023-03-28 14:09:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5811 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [195] => WP_Post Object ( [ID] => 5810 [post_author] => 5 [post_date] => 2022-10-05 12:10:58 [post_date_gmt] => 2022-10-05 12:10:58 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:54:33 [post_modified_gmt] => 2023-04-28 13:54:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5810 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [196] => WP_Post Object ( [ID] => 5807 [post_author] => 5 [post_date] => 2022-10-05 10:53:32 [post_date_gmt] => 2022-10-05 10:53:32 [post_content] => [post_title] => Funder Development Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => funder-development-partnering-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-03-28 13:50:23 [post_modified_gmt] => 2023-03-28 13:50:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5807 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [197] => WP_Post Object ( [ID] => 5809 [post_author] => 5 [post_date] => 2022-10-05 07:50:36 [post_date_gmt] => 2022-10-05 07:50:36 [post_content] => [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => path-aridis-rotavirus-vaccine-development-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-10-05 07:50:36 [post_modified_gmt] => 2022-10-05 07:50:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5809 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [198] => WP_Post Object ( [ID] => 5808 [post_author] => 5 [post_date] => 2022-10-04 10:04:03 [post_date_gmt] => 2022-10-04 10:04:03 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-10-04 10:04:03 [post_modified_gmt] => 2022-10-04 10:04:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [199] => WP_Post Object ( [ID] => 5806 [post_author] => 5 [post_date] => 2022-09-28 14:56:08 [post_date_gmt] => 2022-09-28 14:56:08 [post_content] => [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-09-28 14:56:08 [post_modified_gmt] => 2022-09-28 14:56:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5806 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [200] => WP_Post Object ( [ID] => 5805 [post_author] => 5 [post_date] => 2022-09-28 14:49:39 [post_date_gmt] => 2022-09-28 14:49:39 [post_content] => [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-05-04 11:32:48 [post_modified_gmt] => 2023-05-04 11:32:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5805 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [201] => WP_Post Object ( [ID] => 5804 [post_author] => 5 [post_date] => 2022-09-28 08:20:57 [post_date_gmt] => 2022-09-28 08:20:57 [post_content] => [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-28 08:20:57 [post_modified_gmt] => 2022-09-28 08:20:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5804 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [202] => WP_Post Object ( [ID] => 5803 [post_author] => 5 [post_date] => 2022-09-28 08:09:22 [post_date_gmt] => 2022-09-28 08:09:22 [post_content] => [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-09-28 08:09:22 [post_modified_gmt] => 2022-09-28 08:09:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5803 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [203] => WP_Post Object ( [ID] => 5802 [post_author] => 5 [post_date] => 2022-09-28 08:03:24 [post_date_gmt] => 2022-09-28 08:03:24 [post_content] => [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-09-29 09:02:04 [post_modified_gmt] => 2022-09-29 09:02:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5802 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [204] => WP_Post Object ( [ID] => 5800 [post_author] => 5 [post_date] => 2022-09-28 07:45:10 [post_date_gmt] => 2022-09-28 07:45:10 [post_content] => [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:26:41 [post_modified_gmt] => 2023-05-01 14:26:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5800 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [205] => WP_Post Object ( [ID] => 5799 [post_author] => 5 [post_date] => 2022-09-27 13:35:42 [post_date_gmt] => 2022-09-27 13:35:42 [post_content] => [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-09-27 13:35:42 [post_modified_gmt] => 2022-09-27 13:35:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5799 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [206] => WP_Post Object ( [ID] => 5798 [post_author] => 5 [post_date] => 2022-09-27 13:11:04 [post_date_gmt] => 2022-09-27 13:11:04 [post_content] => [post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-09-29 07:20:44 [post_modified_gmt] => 2022-09-29 07:20:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5798 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [207] => WP_Post Object ( [ID] => 5790 [post_author] => 5 [post_date] => 2022-09-27 09:01:33 [post_date_gmt] => 2022-09-27 09:01:33 [post_content] => [post_title] => Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gilead-mpp-tdf-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-05-04 11:24:23 [post_modified_gmt] => 2023-05-04 11:24:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5790 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [208] => WP_Post Object ( [ID] => 5782 [post_author] => 5 [post_date] => 2022-09-16 07:28:56 [post_date_gmt] => 2022-09-16 07:28:56 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-03-30 14:42:10 [post_modified_gmt] => 2023-03-30 14:42:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5782 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [209] => WP_Post Object ( [ID] => 5781 [post_author] => 5 [post_date] => 2022-09-14 13:33:43 [post_date_gmt] => 2022-09-14 13:33:43 [post_content] => [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-14 13:33:43 [post_modified_gmt] => 2022-09-14 13:33:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5781 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [210] => WP_Post Object ( [ID] => 5779 [post_author] => 5 [post_date] => 2022-09-14 13:01:55 [post_date_gmt] => 2022-09-14 13:01:55 [post_content] => [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-09-14 13:31:15 [post_modified_gmt] => 2022-09-14 13:31:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5779 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [211] => WP_Post Object ( [ID] => 5778 [post_author] => 5 [post_date] => 2022-09-14 11:49:49 [post_date_gmt] => 2022-09-14 11:49:49 [post_content] => [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:16:48 [post_modified_gmt] => 2023-04-28 13:16:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5778 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [212] => WP_Post Object ( [ID] => 5777 [post_author] => 5 [post_date] => 2022-09-14 11:30:25 [post_date_gmt] => 2022-09-14 11:30:25 [post_content] => [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-09-14 11:30:25 [post_modified_gmt] => 2022-09-14 11:30:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5777 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [213] => WP_Post Object ( [ID] => 5776 [post_author] => 5 [post_date] => 2022-09-14 11:17:28 [post_date_gmt] => 2022-09-14 11:17:28 [post_content] => [post_title] => AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:16:21 [post_modified_gmt] => 2023-04-28 13:16:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5776 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [214] => WP_Post Object ( [ID] => 5775 [post_author] => 5 [post_date] => 2022-09-13 13:17:53 [post_date_gmt] => 2022-09-13 13:17:53 [post_content] => [post_title] => AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:15:39 [post_modified_gmt] => 2023-04-28 13:15:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5775 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [215] => WP_Post Object ( [ID] => 5700 [post_author] => 5 [post_date] => 2022-09-07 11:00:26 [post_date_gmt] => 2022-09-07 11:00:26 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-04-04 15:33:42 [post_modified_gmt] => 2023-04-04 15:33:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5700 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [216] => WP_Post Object ( [ID] => 5699 [post_author] => 5 [post_date] => 2022-09-07 10:28:24 [post_date_gmt] => 2022-09-07 10:28:24 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-04-27 12:59:23 [post_modified_gmt] => 2023-04-27 12:59:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5699 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [217] => WP_Post Object ( [ID] => 5698 [post_author] => 5 [post_date] => 2022-09-07 10:14:27 [post_date_gmt] => 2022-09-07 10:14:27 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-03-21 11:44:07 [post_modified_gmt] => 2023-03-21 11:44:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5698 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [218] => WP_Post Object ( [ID] => 5697 [post_author] => 5 [post_date] => 2022-09-07 10:01:19 [post_date_gmt] => 2022-09-07 10:01:19 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-04-04 15:33:31 [post_modified_gmt] => 2023-04-04 15:33:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5697 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [219] => WP_Post Object ( [ID] => 5696 [post_author] => 5 [post_date] => 2022-09-07 09:45:07 [post_date_gmt] => 2022-09-07 09:45:07 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-09-07 09:45:07 [post_modified_gmt] => 2022-09-07 09:45:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5696 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [220] => WP_Post Object ( [ID] => 5695 [post_author] => 5 [post_date] => 2022-09-07 09:35:25 [post_date_gmt] => 2022-09-07 09:35:25 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-09-29 10:38:40 [post_modified_gmt] => 2022-09-29 10:38:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5695 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [221] => WP_Post Object ( [ID] => 5694 [post_author] => 5 [post_date] => 2022-09-07 09:11:50 [post_date_gmt] => 2022-09-07 09:11:50 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:10:06 [post_modified_gmt] => 2023-04-28 13:10:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5694 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [222] => WP_Post Object ( [ID] => 5693 [post_author] => 5 [post_date] => 2022-09-07 08:51:55 [post_date_gmt] => 2022-09-07 08:51:55 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-03-21 11:47:54 [post_modified_gmt] => 2023-03-21 11:47:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5693 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [223] => WP_Post Object ( [ID] => 5692 [post_author] => 5 [post_date] => 2022-09-07 08:21:55 [post_date_gmt] => 2022-09-07 08:21:55 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-04-04 15:33:17 [post_modified_gmt] => 2023-04-04 15:33:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5692 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [224] => WP_Post Object ( [ID] => 5691 [post_author] => 5 [post_date] => 2022-09-07 08:12:00 [post_date_gmt] => 2022-09-07 08:12:00 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:09:05 [post_modified_gmt] => 2023-04-28 13:09:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5691 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [225] => WP_Post Object ( [ID] => 5690 [post_author] => 5 [post_date] => 2022-09-06 18:19:25 [post_date_gmt] => 2022-09-06 18:19:25 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-09-06 18:19:25 [post_modified_gmt] => 2022-09-06 18:19:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5690 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [226] => WP_Post Object ( [ID] => 5689 [post_author] => 5 [post_date] => 2022-09-06 18:09:28 [post_date_gmt] => 2022-09-06 18:09:28 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-04-04 15:33:01 [post_modified_gmt] => 2023-04-04 15:33:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5689 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [227] => WP_Post Object ( [ID] => 5688 [post_author] => 5 [post_date] => 2022-09-06 13:35:23 [post_date_gmt] => 2022-09-06 13:35:23 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:07:33 [post_modified_gmt] => 2023-04-28 13:07:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5688 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [228] => WP_Post Object ( [ID] => 5684 [post_author] => 5 [post_date] => 2022-09-06 13:25:46 [post_date_gmt] => 2022-09-06 13:25:46 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:05:18 [post_modified_gmt] => 2023-04-28 13:05:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5684 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [229] => WP_Post Object ( [ID] => 5683 [post_author] => 5 [post_date] => 2022-09-06 13:02:35 [post_date_gmt] => 2022-09-06 13:02:35 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:04:47 [post_modified_gmt] => 2023-04-28 13:04:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5683 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [230] => WP_Post Object ( [ID] => 5682 [post_author] => 5 [post_date] => 2022-09-06 12:46:39 [post_date_gmt] => 2022-09-06 12:46:39 [post_content] => [post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-27 12:52:42 [post_modified_gmt] => 2023-04-27 12:52:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5682 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [231] => WP_Post Object ( [ID] => 5681 [post_author] => 5 [post_date] => 2022-09-06 12:09:51 [post_date_gmt] => 2022-09-06 12:09:51 [post_content] => [post_title] => Alnylam Pharmaceuticals - University of British Columbia- AlCana Technology, Sponsored Research Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-04 15:32:31 [post_modified_gmt] => 2023-04-04 15:32:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5681 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [232] => WP_Post Object ( [ID] => 5653 [post_author] => 5 [post_date] => 2022-08-25 12:56:30 [post_date_gmt] => 2022-08-25 12:56:30 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-03-30 14:41:50 [post_modified_gmt] => 2023-03-30 14:41:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5653 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [233] => WP_Post Object ( [ID] => 5652 [post_author] => 5 [post_date] => 2022-08-25 12:26:53 [post_date_gmt] => 2022-08-25 12:26:53 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:46:10 [post_modified_gmt] => 2023-01-10 11:46:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5652 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [234] => WP_Post Object ( [ID] => 5634 [post_author] => 5 [post_date] => 2022-08-22 13:18:41 [post_date_gmt] => 2022-08-22 13:18:41 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-08-22 13:18:41 [post_modified_gmt] => 2022-08-22 13:18:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5634 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [235] => WP_Post Object ( [ID] => 5633 [post_author] => 5 [post_date] => 2022-08-22 13:15:31 [post_date_gmt] => 2022-08-22 13:15:31 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-09-29 10:49:29 [post_modified_gmt] => 2022-09-29 10:49:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5633 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [236] => WP_Post Object ( [ID] => 5632 [post_author] => 5 [post_date] => 2022-08-22 13:03:54 [post_date_gmt] => 2022-08-22 13:03:54 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-04-27 07:11:15 [post_modified_gmt] => 2023-04-27 07:11:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5632 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [237] => WP_Post Object ( [ID] => 5631 [post_author] => 5 [post_date] => 2022-08-22 12:52:49 [post_date_gmt] => 2022-08-22 12:52:49 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-08-22 12:52:49 [post_modified_gmt] => 2022-08-22 12:52:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5631 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [238] => WP_Post Object ( [ID] => 5629 [post_author] => 5 [post_date] => 2022-08-22 12:19:52 [post_date_gmt] => 2022-08-22 12:19:52 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-08-22 12:28:27 [post_modified_gmt] => 2022-08-22 12:28:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5629 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [239] => WP_Post Object ( [ID] => 5627 [post_author] => 5 [post_date] => 2022-08-22 11:56:36 [post_date_gmt] => 2022-08-22 11:56:36 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-08-22 11:56:36 [post_modified_gmt] => 2022-08-22 11:56:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5627 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [240] => WP_Post Object ( [ID] => 5626 [post_author] => 5 [post_date] => 2022-08-22 11:12:04 [post_date_gmt] => 2022-08-22 11:12:04 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:26:35 [post_modified_gmt] => 2023-04-28 13:26:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5626 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [241] => WP_Post Object ( [ID] => 5624 [post_author] => 5 [post_date] => 2022-08-17 08:56:52 [post_date_gmt] => 2022-08-17 08:56:52 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-08-17 08:56:52 [post_modified_gmt] => 2022-08-17 08:56:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5624 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [242] => WP_Post Object ( [ID] => 5623 [post_author] => 5 [post_date] => 2022-08-16 15:29:11 [post_date_gmt] => 2022-08-16 15:29:11 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-09-20 12:53:18 [post_modified_gmt] => 2022-09-20 12:53:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5623 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [243] => WP_Post Object ( [ID] => 5622 [post_author] => 5 [post_date] => 2022-08-16 14:49:36 [post_date_gmt] => 2022-08-16 14:49:36 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-05-02 13:21:15 [post_modified_gmt] => 2023-05-02 13:21:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5622 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [244] => WP_Post Object ( [ID] => 5620 [post_author] => 5 [post_date] => 2022-08-12 12:05:12 [post_date_gmt] => 2022-08-12 12:05:12 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-08-12 12:05:12 [post_modified_gmt] => 2022-08-12 12:05:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5620 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [245] => WP_Post Object ( [ID] => 5619 [post_author] => 5 [post_date] => 2022-08-12 12:02:21 [post_date_gmt] => 2022-08-12 12:02:21 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:48:01 [post_modified_gmt] => 2022-10-12 12:48:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5619 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [246] => WP_Post Object ( [ID] => 5618 [post_author] => 5 [post_date] => 2022-08-12 11:52:17 [post_date_gmt] => 2022-08-12 11:52:17 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-08-12 11:52:17 [post_modified_gmt] => 2022-08-12 11:52:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5618 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [247] => WP_Post Object ( [ID] => 5617 [post_author] => 5 [post_date] => 2022-08-12 11:49:46 [post_date_gmt] => 2022-08-12 11:49:46 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-08-12 11:49:46 [post_modified_gmt] => 2022-08-12 11:49:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5617 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [248] => WP_Post Object ( [ID] => 5616 [post_author] => 5 [post_date] => 2022-08-12 11:45:22 [post_date_gmt] => 2022-08-12 11:45:22 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-08-12 11:45:22 [post_modified_gmt] => 2022-08-12 11:45:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5616 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [249] => WP_Post Object ( [ID] => 5615 [post_author] => 5 [post_date] => 2022-08-12 11:40:08 [post_date_gmt] => 2022-08-12 11:40:08 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-08-12 11:40:08 [post_modified_gmt] => 2022-08-12 11:40:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5615 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [250] => WP_Post Object ( [ID] => 5614 [post_author] => 5 [post_date] => 2022-08-12 11:34:41 [post_date_gmt] => 2022-08-12 11:34:41 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-29 11:28:05 [post_modified_gmt] => 2022-09-29 11:28:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5614 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [251] => WP_Post Object ( [ID] => 5612 [post_author] => 5 [post_date] => 2022-08-12 10:14:31 [post_date_gmt] => 2022-08-12 10:14:31 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-12-14 13:42:46 [post_modified_gmt] => 2022-12-14 13:42:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5612 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [252] => WP_Post Object ( [ID] => 5611 [post_author] => 5 [post_date] => 2022-08-12 10:05:33 [post_date_gmt] => 2022-08-12 10:05:33 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-08-12 10:05:33 [post_modified_gmt] => 2022-08-12 10:05:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5611 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [253] => WP_Post Object ( [ID] => 5610 [post_author] => 5 [post_date] => 2022-08-12 09:31:00 [post_date_gmt] => 2022-08-12 09:31:00 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:10:06 [post_modified_gmt] => 2023-03-28 14:10:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5610 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [254] => WP_Post Object ( [ID] => 5609 [post_author] => 5 [post_date] => 2022-08-12 09:24:43 [post_date_gmt] => 2022-08-12 09:24:43 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-08-12 09:24:43 [post_modified_gmt] => 2022-08-12 09:24:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5609 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [255] => WP_Post Object ( [ID] => 5608 [post_author] => 5 [post_date] => 2022-08-12 09:09:54 [post_date_gmt] => 2022-08-12 09:09:54 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-27 08:36:41 [post_modified_gmt] => 2023-04-27 08:36:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5608 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [256] => WP_Post Object ( [ID] => 5599 [post_author] => 5 [post_date] => 2022-08-11 14:17:45 [post_date_gmt] => 2022-08-11 14:17:45 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:23:07 [post_modified_gmt] => 2023-05-01 14:23:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5599 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [257] => WP_Post Object ( [ID] => 5596 [post_author] => 5 [post_date] => 2022-08-11 12:52:07 [post_date_gmt] => 2022-08-11 12:52:07 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-11-08 18:52:16 [post_modified_gmt] => 2022-11-08 18:52:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5596 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [258] => WP_Post Object ( [ID] => 5595 [post_author] => 5 [post_date] => 2022-08-11 12:36:15 [post_date_gmt] => 2022-08-11 12:36:15 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-08-11 12:36:15 [post_modified_gmt] => 2022-08-11 12:36:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5595 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [259] => WP_Post Object ( [ID] => 5594 [post_author] => 5 [post_date] => 2022-08-11 12:13:32 [post_date_gmt] => 2022-08-11 12:13:32 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:22:41 [post_modified_gmt] => 2023-05-01 14:22:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5594 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [260] => WP_Post Object ( [ID] => 5593 [post_author] => 5 [post_date] => 2022-08-11 11:48:52 [post_date_gmt] => 2022-08-11 11:48:52 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-08-11 12:26:53 [post_modified_gmt] => 2022-08-11 12:26:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5593 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [261] => WP_Post Object ( [ID] => 5592 [post_author] => 5 [post_date] => 2022-08-11 11:16:19 [post_date_gmt] => 2022-08-11 11:16:19 [post_content] => [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-10-13 13:12:08 [post_modified_gmt] => 2022-10-13 13:12:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5592 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [262] => WP_Post Object ( [ID] => 5591 [post_author] => 5 [post_date] => 2022-08-11 10:18:46 [post_date_gmt] => 2022-08-11 10:18:46 [post_content] => [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement [to_ping] => [pinged] => [post_modified] => 2022-08-11 10:18:46 [post_modified_gmt] => 2022-08-11 10:18:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5591 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [263] => WP_Post Object ( [ID] => 5429 [post_author] => 5 [post_date] => 2022-07-25 06:51:00 [post_date_gmt] => 2022-07-25 06:51:00 [post_content] => [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-05-04 12:00:45 [post_modified_gmt] => 2023-05-04 12:00:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5429 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [264] => WP_Post Object ( [ID] => 5427 [post_author] => 5 [post_date] => 2022-07-22 15:20:29 [post_date_gmt] => 2022-07-22 15:20:29 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:34:01 [post_modified_gmt] => 2023-04-28 13:34:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5427 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [265] => WP_Post Object ( [ID] => 5286 [post_author] => 5 [post_date] => 2022-07-08 13:44:08 [post_date_gmt] => 2022-07-08 13:44:08 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-18 [to_ping] => [pinged] => [post_modified] => 2022-07-12 11:31:31 [post_modified_gmt] => 2022-07-12 11:31:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5286 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [266] => WP_Post Object ( [ID] => 5285 [post_author] => 5 [post_date] => 2022-07-08 13:33:14 [post_date_gmt] => 2022-07-08 13:33:14 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:41:56 [post_modified_gmt] => 2023-04-27 11:41:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5285 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [267] => WP_Post Object ( [ID] => 5284 [post_author] => 5 [post_date] => 2022-07-08 13:17:26 [post_date_gmt] => 2022-07-08 13:17:26 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-07-12 11:30:52 [post_modified_gmt] => 2022-07-12 11:30:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5284 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [268] => WP_Post Object ( [ID] => 5283 [post_author] => 5 [post_date] => 2022-07-08 13:03:43 [post_date_gmt] => 2022-07-08 13:03:43 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-07-12 11:25:34 [post_modified_gmt] => 2022-07-12 11:25:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5283 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [269] => WP_Post Object ( [ID] => 5282 [post_author] => 5 [post_date] => 2022-07-08 13:00:08 [post_date_gmt] => 2022-07-08 13:00:08 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:39:53 [post_modified_gmt] => 2023-04-27 11:39:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5282 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [270] => WP_Post Object ( [ID] => 5281 [post_author] => 5 [post_date] => 2022-07-08 12:00:54 [post_date_gmt] => 2022-07-08 12:00:54 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-05-17 10:14:06 [post_modified_gmt] => 2023-05-17 10:14:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5281 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [271] => WP_Post Object ( [ID] => 5280 [post_author] => 5 [post_date] => 2022-07-08 11:46:11 [post_date_gmt] => 2022-07-08 11:46:11 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:03:14 [post_modified_gmt] => 2022-10-12 11:03:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5280 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [272] => WP_Post Object ( [ID] => 5279 [post_author] => 5 [post_date] => 2022-07-08 10:36:09 [post_date_gmt] => 2022-07-08 10:36:09 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-02-03 13:44:48 [post_modified_gmt] => 2023-02-03 13:44:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5279 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [273] => WP_Post Object ( [ID] => 5278 [post_author] => 5 [post_date] => 2022-07-08 10:25:20 [post_date_gmt] => 2022-07-08 10:25:20 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:41:51 [post_modified_gmt] => 2023-05-01 14:41:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5278 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [274] => WP_Post Object ( [ID] => 5277 [post_author] => 5 [post_date] => 2022-07-08 10:12:53 [post_date_gmt] => 2022-07-08 10:12:53 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-07-11 13:26:16 [post_modified_gmt] => 2022-07-11 13:26:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5277 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [275] => WP_Post Object ( [ID] => 5276 [post_author] => 5 [post_date] => 2022-07-08 10:04:48 [post_date_gmt] => 2022-07-08 10:04:48 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-09-27 09:53:02 [post_modified_gmt] => 2022-09-27 09:53:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5276 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [276] => WP_Post Object ( [ID] => 5275 [post_author] => 5 [post_date] => 2022-07-08 09:34:04 [post_date_gmt] => 2022-07-08 09:34:04 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-07-11 12:22:08 [post_modified_gmt] => 2022-07-11 12:22:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5275 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [277] => WP_Post Object ( [ID] => 5274 [post_author] => 5 [post_date] => 2022-07-08 09:14:56 [post_date_gmt] => 2022-07-08 09:14:56 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:48:27 [post_modified_gmt] => 2022-10-12 12:48:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5274 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [278] => WP_Post Object ( [ID] => 5273 [post_author] => 5 [post_date] => 2022-07-08 08:33:17 [post_date_gmt] => 2022-07-08 08:33:17 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-07-11 10:55:22 [post_modified_gmt] => 2022-07-11 10:55:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5273 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [279] => WP_Post Object ( [ID] => 5272 [post_author] => 5 [post_date] => 2022-07-08 08:28:02 [post_date_gmt] => 2022-07-08 08:28:02 [post_content] => [post_title] => Shionogi – GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:36:50 [post_modified_gmt] => 2023-04-27 11:36:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5272 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [280] => WP_Post Object ( [ID] => 5271 [post_author] => 5 [post_date] => 2022-07-08 08:21:14 [post_date_gmt] => 2022-07-08 08:21:14 [post_content] => [post_title] => Shionogi - GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-07-13 13:44:53 [post_modified_gmt] => 2022-07-13 13:44:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5271 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [281] => WP_Post Object ( [ID] => 5270 [post_author] => 5 [post_date] => 2022-07-08 08:12:42 [post_date_gmt] => 2022-07-08 08:12:42 [post_content] => [post_title] => Shionogi - GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:35:25 [post_modified_gmt] => 2023-04-27 11:35:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5270 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [282] => WP_Post Object ( [ID] => 5269 [post_author] => 5 [post_date] => 2022-07-08 07:47:02 [post_date_gmt] => 2022-07-08 07:47:02 [post_content] => [post_title] => Shionogi - GARDP, Cefiderocol License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => shionogi-gardp-cefiderocol-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-07-13 11:52:37 [post_modified_gmt] => 2022-07-13 11:52:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5269 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [283] => WP_Post Object ( [ID] => 5123 [post_author] => 5 [post_date] => 2022-06-29 15:28:35 [post_date_gmt] => 2022-06-29 15:28:35 [post_content] => [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-04-05 12:27:11 [post_modified_gmt] => 2023-04-05 12:27:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5123 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [284] => WP_Post Object ( [ID] => 5122 [post_author] => 5 [post_date] => 2022-06-29 14:42:34 [post_date_gmt] => 2022-06-29 14:42:34 [post_content] => [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => 5122 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:03:44 [post_modified_gmt] => 2022-10-12 11:03:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5122 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [285] => WP_Post Object ( [ID] => 5121 [post_author] => 5 [post_date] => 2022-06-29 14:38:19 [post_date_gmt] => 2022-06-29 14:38:19 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-04-05 12:21:33 [post_modified_gmt] => 2023-04-05 12:21:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5121 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [286] => WP_Post Object ( [ID] => 5120 [post_author] => 5 [post_date] => 2022-06-29 14:30:21 [post_date_gmt] => 2022-06-29 14:30:21 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-06-29 14:30:21 [post_modified_gmt] => 2022-06-29 14:30:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5120 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [287] => WP_Post Object ( [ID] => 5119 [post_author] => 5 [post_date] => 2022-06-29 14:09:28 [post_date_gmt] => 2022-06-29 14:09:28 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-06-29 14:09:28 [post_modified_gmt] => 2022-06-29 14:09:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5119 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [288] => WP_Post Object ( [ID] => 5118 [post_author] => 5 [post_date] => 2022-06-29 14:05:52 [post_date_gmt] => 2022-06-29 14:05:52 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-04-05 12:21:18 [post_modified_gmt] => 2023-04-05 12:21:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5118 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [289] => WP_Post Object ( [ID] => 5117 [post_author] => 5 [post_date] => 2022-06-29 14:02:42 [post_date_gmt] => 2022-06-29 14:02:42 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-06-29 14:02:42 [post_modified_gmt] => 2022-06-29 14:02:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5117 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [290] => WP_Post Object ( [ID] => 5116 [post_author] => 5 [post_date] => 2022-06-29 14:00:58 [post_date_gmt] => 2022-06-29 14:00:58 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-06-29 14:00:58 [post_modified_gmt] => 2022-06-29 14:00:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5116 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [291] => WP_Post Object ( [ID] => 5115 [post_author] => 5 [post_date] => 2022-06-29 13:52:08 [post_date_gmt] => 2022-06-29 13:52:08 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:48:53 [post_modified_gmt] => 2022-10-12 12:48:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5115 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [292] => WP_Post Object ( [ID] => 5114 [post_author] => 5 [post_date] => 2022-06-29 13:46:01 [post_date_gmt] => 2022-06-29 13:46:01 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-06-29 15:10:31 [post_modified_gmt] => 2022-06-29 15:10:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5114 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [293] => WP_Post Object ( [ID] => 5113 [post_author] => 5 [post_date] => 2022-06-29 13:33:56 [post_date_gmt] => 2022-06-29 13:33:56 [post_content] => [post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-03-21 12:38:36 [post_modified_gmt] => 2023-03-21 12:38:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5113 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [294] => WP_Post Object ( [ID] => 5112 [post_author] => 5 [post_date] => 2022-06-29 13:04:55 [post_date_gmt] => 2022-06-29 13:04:55 [post_content] => [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-07-13 13:33:12 [post_modified_gmt] => 2022-07-13 13:33:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5112 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [295] => WP_Post Object ( [ID] => 5111 [post_author] => 5 [post_date] => 2022-06-29 12:40:35 [post_date_gmt] => 2022-06-29 12:40:35 [post_content] => [post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-05 12:19:57 [post_modified_gmt] => 2023-04-05 12:19:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=5111 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [296] => WP_Post Object ( [ID] => 4894 [post_author] => 5 [post_date] => 2022-06-08 13:01:48 [post_date_gmt] => 2022-06-08 13:01:48 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-06-09 12:23:23 [post_modified_gmt] => 2022-06-09 12:23:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4894 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [297] => WP_Post Object ( [ID] => 4893 [post_author] => 5 [post_date] => 2022-06-08 12:28:46 [post_date_gmt] => 2022-06-08 12:28:46 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-05-17 10:01:04 [post_modified_gmt] => 2023-05-17 10:01:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4893 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [298] => WP_Post Object ( [ID] => 4892 [post_author] => 5 [post_date] => 2022-06-08 11:21:42 [post_date_gmt] => 2022-06-08 11:21:42 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:50:39 [post_modified_gmt] => 2023-04-28 13:50:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4892 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [299] => WP_Post Object ( [ID] => 4891 [post_author] => 5 [post_date] => 2022-06-08 10:28:17 [post_date_gmt] => 2022-06-08 10:28:17 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:50:13 [post_modified_gmt] => 2023-04-28 13:50:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4891 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [300] => WP_Post Object ( [ID] => 4890 [post_author] => 5 [post_date] => 2022-06-08 10:10:04 [post_date_gmt] => 2022-06-08 10:10:04 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-06-09 12:29:11 [post_modified_gmt] => 2022-06-09 12:29:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4890 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [301] => WP_Post Object ( [ID] => 4889 [post_author] => 5 [post_date] => 2022-06-08 10:04:27 [post_date_gmt] => 2022-06-08 10:04:27 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-06-09 12:28:42 [post_modified_gmt] => 2022-06-09 12:28:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4889 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [302] => WP_Post Object ( [ID] => 4888 [post_author] => 5 [post_date] => 2022-06-08 09:09:43 [post_date_gmt] => 2022-06-08 09:09:43 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-06-09 12:28:01 [post_modified_gmt] => 2022-06-09 12:28:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4888 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [303] => WP_Post Object ( [ID] => 4886 [post_author] => 5 [post_date] => 2022-06-08 08:43:51 [post_date_gmt] => 2022-06-08 08:43:51 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-06-09 12:27:40 [post_modified_gmt] => 2022-06-09 12:27:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4886 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [304] => WP_Post Object ( [ID] => 4885 [post_author] => 5 [post_date] => 2022-06-08 08:36:01 [post_date_gmt] => 2022-06-08 08:36:01 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-09-29 11:22:57 [post_modified_gmt] => 2022-09-29 11:22:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4885 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [305] => WP_Post Object ( [ID] => 4884 [post_author] => 5 [post_date] => 2022-06-08 07:54:05 [post_date_gmt] => 2022-06-08 07:54:05 [post_content] => [post_title] => Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-06-09 12:24:23 [post_modified_gmt] => 2022-06-09 12:24:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4884 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [306] => WP_Post Object ( [ID] => 4883 [post_author] => 5 [post_date] => 2022-06-08 07:25:31 [post_date_gmt] => 2022-06-08 07:25:31 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-04-11 15:04:43 [post_modified_gmt] => 2023-04-11 15:04:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4883 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [307] => WP_Post Object ( [ID] => 4882 [post_author] => 5 [post_date] => 2022-06-08 07:14:04 [post_date_gmt] => 2022-06-08 07:14:04 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:51:59 [post_modified_gmt] => 2022-09-26 14:51:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4882 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [308] => WP_Post Object ( [ID] => 4881 [post_author] => 5 [post_date] => 2022-06-07 13:58:33 [post_date_gmt] => 2022-06-07 13:58:33 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-06-09 12:25:30 [post_modified_gmt] => 2022-06-09 12:25:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4881 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [309] => WP_Post Object ( [ID] => 4878 [post_author] => 5 [post_date] => 2022-06-07 13:47:24 [post_date_gmt] => 2022-06-07 13:47:24 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:49:28 [post_modified_gmt] => 2022-10-12 12:49:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4878 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [310] => WP_Post Object ( [ID] => 4877 [post_author] => 5 [post_date] => 2022-06-07 13:22:01 [post_date_gmt] => 2022-06-07 13:22:01 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:49:34 [post_modified_gmt] => 2023-04-28 13:49:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4877 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [311] => WP_Post Object ( [ID] => 4876 [post_author] => 5 [post_date] => 2022-06-07 13:03:57 [post_date_gmt] => 2022-06-07 13:03:57 [post_content] => [post_title] => Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-27 12:40:18 [post_modified_gmt] => 2023-04-27 12:40:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4876 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [312] => WP_Post Object ( [ID] => 4875 [post_author] => 5 [post_date] => 2022-06-07 11:48:34 [post_date_gmt] => 2022-06-07 11:48:34 [post_content] => [post_title] => Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhoea-medication-collaboration-agreement [to_ping] => [pinged] => [post_modified] => 2022-10-13 13:13:57 [post_modified_gmt] => 2022-10-13 13:13:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4875 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [313] => WP_Post Object ( [ID] => 4873 [post_author] => 5 [post_date] => 2022-06-07 11:31:58 [post_date_gmt] => 2022-06-07 11:31:58 [post_content] => [post_title] => Entasis - DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => entasis-dndi-gardp-gonorrhea-medication-collaboration-agreement [to_ping] => [pinged] => [post_modified] => 2022-07-13 09:30:15 [post_modified_gmt] => 2022-07-13 09:30:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4873 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [314] => WP_Post Object ( [ID] => 4869 [post_author] => 5 [post_date] => 2022-06-07 10:16:47 [post_date_gmt] => 2022-06-07 10:16:47 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-12 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:25:42 [post_modified_gmt] => 2023-04-28 13:25:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4869 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [315] => WP_Post Object ( [ID] => 4868 [post_author] => 5 [post_date] => 2022-06-07 09:30:21 [post_date_gmt] => 2022-06-07 09:30:21 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-11 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:04:43 [post_modified_gmt] => 2022-10-12 11:04:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4868 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [316] => WP_Post Object ( [ID] => 4867 [post_author] => 5 [post_date] => 2022-06-07 09:14:39 [post_date_gmt] => 2022-06-07 09:14:39 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-10 [to_ping] => [pinged] => [post_modified] => 2022-06-07 09:14:39 [post_modified_gmt] => 2022-06-07 09:14:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4867 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [317] => WP_Post Object ( [ID] => 4866 [post_author] => 5 [post_date] => 2022-06-07 08:53:11 [post_date_gmt] => 2022-06-07 08:53:11 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-9 [to_ping] => [pinged] => [post_modified] => 2022-06-07 08:53:11 [post_modified_gmt] => 2022-06-07 08:53:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4866 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [318] => WP_Post Object ( [ID] => 4865 [post_author] => 5 [post_date] => 2022-06-07 08:46:16 [post_date_gmt] => 2022-06-07 08:46:16 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-8 [to_ping] => [pinged] => [post_modified] => 2023-03-21 12:42:24 [post_modified_gmt] => 2023-03-21 12:42:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4865 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [319] => WP_Post Object ( [ID] => 4864 [post_author] => 5 [post_date] => 2022-06-07 08:29:48 [post_date_gmt] => 2022-06-07 08:29:48 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-7 [to_ping] => [pinged] => [post_modified] => 2023-03-21 12:40:58 [post_modified_gmt] => 2023-03-21 12:40:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4864 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [320] => WP_Post Object ( [ID] => 4863 [post_author] => 5 [post_date] => 2022-06-06 14:26:47 [post_date_gmt] => 2022-06-06 14:26:47 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-6 [to_ping] => [pinged] => [post_modified] => 2022-07-06 09:55:41 [post_modified_gmt] => 2022-07-06 09:55:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4863 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [321] => WP_Post Object ( [ID] => 4862 [post_author] => 5 [post_date] => 2022-06-06 14:20:32 [post_date_gmt] => 2022-06-06 14:20:32 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-5 [to_ping] => [pinged] => [post_modified] => 2022-06-06 14:20:32 [post_modified_gmt] => 2022-06-06 14:20:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4862 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [322] => WP_Post Object ( [ID] => 4861 [post_author] => 5 [post_date] => 2022-06-06 13:55:49 [post_date_gmt] => 2022-06-06 13:55:49 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-4 [to_ping] => [pinged] => [post_modified] => 2023-03-21 12:41:33 [post_modified_gmt] => 2023-03-21 12:41:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4861 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [323] => WP_Post Object ( [ID] => 4860 [post_author] => 5 [post_date] => 2022-06-06 13:12:22 [post_date_gmt] => 2022-06-06 13:12:22 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-3 [to_ping] => [pinged] => [post_modified] => 2022-06-06 13:12:22 [post_modified_gmt] => 2022-06-06 13:12:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4860 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [324] => WP_Post Object ( [ID] => 4859 [post_author] => 5 [post_date] => 2022-06-06 12:38:41 [post_date_gmt] => 2022-06-06 12:38:41 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template-2 [to_ping] => [pinged] => [post_modified] => 2023-05-08 13:07:20 [post_modified_gmt] => 2023-05-08 13:07:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4859 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [325] => WP_Post Object ( [ID] => 4858 [post_author] => 5 [post_date] => 2022-06-02 12:35:22 [post_date_gmt] => 2022-06-02 12:35:22 [post_content] => [post_title] => Boston University Startup Exclusive License Template [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => boston-university-startup-exclusive-license-template [to_ping] => [pinged] => [post_modified] => 2022-06-02 13:02:59 [post_modified_gmt] => 2022-06-02 13:02:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4858 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [326] => WP_Post Object ( [ID] => 4857 [post_author] => 5 [post_date] => 2022-06-02 10:16:52 [post_date_gmt] => 2022-06-02 10:16:52 [post_content] => [post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-curevac-global-access-commitments-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:06:21 [post_modified_gmt] => 2022-10-12 11:06:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4857 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [327] => WP_Post Object ( [ID] => 4855 [post_author] => 5 [post_date] => 2022-06-01 11:59:15 [post_date_gmt] => 2022-06-01 11:59:15 [post_content] => [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-7 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:39:39 [post_modified_gmt] => 2022-08-11 09:39:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4855 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [328] => WP_Post Object ( [ID] => 4853 [post_author] => 5 [post_date] => 2022-06-01 11:47:22 [post_date_gmt] => 2022-06-01 11:47:22 [post_content] => [post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-6 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:40:07 [post_modified_gmt] => 2022-08-11 09:40:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4853 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [329] => WP_Post Object ( [ID] => 4850 [post_author] => 5 [post_date] => 2022-05-31 10:27:15 [post_date_gmt] => 2022-05-31 10:27:15 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:06:38 [post_modified_gmt] => 2022-10-12 11:06:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4850 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [330] => WP_Post Object ( [ID] => 4849 [post_author] => 5 [post_date] => 2022-05-31 10:09:48 [post_date_gmt] => 2022-05-31 10:09:48 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:51:11 [post_modified_gmt] => 2022-09-26 14:51:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4849 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [331] => WP_Post Object ( [ID] => 4848 [post_author] => 5 [post_date] => 2022-05-31 09:49:03 [post_date_gmt] => 2022-05-31 09:49:03 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-05-31 10:11:26 [post_modified_gmt] => 2022-05-31 10:11:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4848 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [332] => WP_Post Object ( [ID] => 4847 [post_author] => 5 [post_date] => 2022-05-31 09:19:59 [post_date_gmt] => 2022-05-31 09:19:59 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-05-31 09:19:59 [post_modified_gmt] => 2022-05-31 09:19:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4847 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [333] => WP_Post Object ( [ID] => 4846 [post_author] => 5 [post_date] => 2022-05-31 09:13:07 [post_date_gmt] => 2022-05-31 09:13:07 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-05-31 09:13:58 [post_modified_gmt] => 2022-05-31 09:13:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4846 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [334] => WP_Post Object ( [ID] => 4845 [post_author] => 5 [post_date] => 2022-05-31 08:57:11 [post_date_gmt] => 2022-05-31 08:57:11 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-05-31 09:01:01 [post_modified_gmt] => 2022-05-31 09:01:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4845 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [335] => WP_Post Object ( [ID] => 4844 [post_author] => 5 [post_date] => 2022-05-31 08:52:57 [post_date_gmt] => 2022-05-31 08:52:57 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-05-31 08:52:57 [post_modified_gmt] => 2022-05-31 08:52:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4844 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [336] => WP_Post Object ( [ID] => 4843 [post_author] => 5 [post_date] => 2022-05-31 08:47:53 [post_date_gmt] => 2022-05-31 08:47:53 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-09-29 11:19:47 [post_modified_gmt] => 2022-09-29 11:19:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4843 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [337] => WP_Post Object ( [ID] => 4842 [post_author] => 5 [post_date] => 2022-05-31 08:33:58 [post_date_gmt] => 2022-05-31 08:33:58 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-04-27 12:37:54 [post_modified_gmt] => 2023-04-27 12:37:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4842 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [338] => WP_Post Object ( [ID] => 4841 [post_author] => 5 [post_date] => 2022-05-31 08:22:01 [post_date_gmt] => 2022-05-31 08:22:01 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:51:15 [post_modified_gmt] => 2022-10-12 12:51:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4841 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [339] => WP_Post Object ( [ID] => 4840 [post_author] => 5 [post_date] => 2022-05-31 08:10:32 [post_date_gmt] => 2022-05-31 08:10:32 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-03-31 10:58:47 [post_modified_gmt] => 2023-03-31 10:58:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4840 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [340] => WP_Post Object ( [ID] => 4838 [post_author] => 5 [post_date] => 2022-05-27 15:01:58 [post_date_gmt] => 2022-05-27 15:01:58 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-05-05 09:46:07 [post_modified_gmt] => 2023-05-05 09:46:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4838 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [341] => WP_Post Object ( [ID] => 4837 [post_author] => 5 [post_date] => 2022-05-27 14:43:04 [post_date_gmt] => 2022-05-27 14:43:04 [post_content] => [post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-07-13 12:57:32 [post_modified_gmt] => 2022-07-13 12:57:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4837 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [342] => WP_Post Object ( [ID] => 4835 [post_author] => 5 [post_date] => 2022-05-27 14:00:10 [post_date_gmt] => 2022-05-27 14:00:10 [post_content] => [post_title] => Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-05-05 09:43:34 [post_modified_gmt] => 2023-05-05 09:43:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4835 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [343] => WP_Post Object ( [ID] => 4834 [post_author] => 5 [post_date] => 2022-05-27 13:26:16 [post_date_gmt] => 2022-05-27 13:26:16 [post_content] => [post_title] => Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-07-13 09:28:10 [post_modified_gmt] => 2022-07-13 09:28:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4834 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [344] => WP_Post Object ( [ID] => 4808 [post_author] => 5 [post_date] => 2022-05-24 09:09:54 [post_date_gmt] => 2022-05-24 09:09:54 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:40:46 [post_modified_gmt] => 2023-04-28 13:40:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [345] => WP_Post Object ( [ID] => 4807 [post_author] => 5 [post_date] => 2022-05-24 09:02:55 [post_date_gmt] => 2022-05-24 09:02:55 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-05-24 09:02:55 [post_modified_gmt] => 2022-05-24 09:02:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4807 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [346] => WP_Post Object ( [ID] => 4806 [post_author] => 5 [post_date] => 2022-05-24 08:59:08 [post_date_gmt] => 2022-05-24 08:59:08 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:40:29 [post_modified_gmt] => 2023-04-28 13:40:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4806 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [347] => WP_Post Object ( [ID] => 4805 [post_author] => 5 [post_date] => 2022-05-24 08:53:12 [post_date_gmt] => 2022-05-24 08:53:12 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:59:42 [post_modified_gmt] => 2022-05-24 08:59:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4805 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [348] => WP_Post Object ( [ID] => 4804 [post_author] => 5 [post_date] => 2022-05-24 08:40:15 [post_date_gmt] => 2022-05-24 08:40:15 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:53:51 [post_modified_gmt] => 2022-05-24 08:53:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4804 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [349] => WP_Post Object ( [ID] => 4802 [post_author] => 5 [post_date] => 2022-05-24 08:24:23 [post_date_gmt] => 2022-05-24 08:24:23 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:24:23 [post_modified_gmt] => 2022-05-24 08:24:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4802 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [350] => WP_Post Object ( [ID] => 4801 [post_author] => 5 [post_date] => 2022-05-24 08:19:21 [post_date_gmt] => 2022-05-24 08:19:21 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:40:03 [post_modified_gmt] => 2023-04-28 13:40:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4801 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [351] => WP_Post Object ( [ID] => 4800 [post_author] => 5 [post_date] => 2022-05-24 08:07:39 [post_date_gmt] => 2022-05-24 08:07:39 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:53:27 [post_modified_gmt] => 2022-10-12 12:53:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4800 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [352] => WP_Post Object ( [ID] => 4798 [post_author] => 5 [post_date] => 2022-05-23 14:11:13 [post_date_gmt] => 2022-05-23 14:11:13 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-02-03 13:36:05 [post_modified_gmt] => 2023-02-03 13:36:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4798 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [353] => WP_Post Object ( [ID] => 4797 [post_author] => 5 [post_date] => 2022-05-23 13:54:57 [post_date_gmt] => 2022-05-23 13:54:57 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-07-13 12:28:31 [post_modified_gmt] => 2022-07-13 12:28:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4797 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [354] => WP_Post Object ( [ID] => 4796 [post_author] => 5 [post_date] => 2022-05-23 13:54:05 [post_date_gmt] => 2022-05-23 13:54:05 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:39:34 [post_modified_gmt] => 2023-04-28 13:39:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4796 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [355] => WP_Post Object ( [ID] => 4704 [post_author] => 5 [post_date] => 2022-04-26 15:08:03 [post_date_gmt] => 2022-04-26 15:08:03 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:12:02 [post_modified_gmt] => 2022-10-12 11:12:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4704 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [356] => WP_Post Object ( [ID] => 4703 [post_author] => 5 [post_date] => 2022-04-26 14:56:55 [post_date_gmt] => 2022-04-26 14:56:55 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:42:15 [post_modified_gmt] => 2022-08-11 09:42:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4703 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [357] => WP_Post Object ( [ID] => 4702 [post_author] => 5 [post_date] => 2022-04-26 14:46:00 [post_date_gmt] => 2022-04-26 14:46:00 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-04-27 08:32:42 [post_modified_gmt] => 2023-04-27 08:32:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4702 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [358] => WP_Post Object ( [ID] => 4701 [post_author] => 5 [post_date] => 2022-04-26 14:30:45 [post_date_gmt] => 2022-04-26 14:30:45 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:43:48 [post_modified_gmt] => 2022-08-11 09:43:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4701 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [359] => WP_Post Object ( [ID] => 4700 [post_author] => 5 [post_date] => 2022-04-26 14:23:46 [post_date_gmt] => 2022-04-26 14:23:46 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-29 11:26:36 [post_modified_gmt] => 2022-09-29 11:26:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4700 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [360] => WP_Post Object ( [ID] => 4699 [post_author] => 5 [post_date] => 2022-04-26 14:06:18 [post_date_gmt] => 2022-04-26 14:06:18 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-04-28 14:26:15 [post_modified_gmt] => 2023-04-28 14:26:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4699 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [361] => WP_Post Object ( [ID] => 4698 [post_author] => 5 [post_date] => 2022-04-26 12:27:58 [post_date_gmt] => 2022-04-26 12:27:58 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:54:04 [post_modified_gmt] => 2022-10-12 12:54:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4698 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [362] => WP_Post Object ( [ID] => 4697 [post_author] => 5 [post_date] => 2022-04-26 12:05:54 [post_date_gmt] => 2022-04-26 12:05:54 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:44:46 [post_modified_gmt] => 2022-08-11 09:44:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4697 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [363] => WP_Post Object ( [ID] => 4696 [post_author] => 5 [post_date] => 2022-04-26 11:05:38 [post_date_gmt] => 2022-04-26 11:05:38 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-28 14:25:40 [post_modified_gmt] => 2023-04-28 14:25:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4696 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [364] => WP_Post Object ( [ID] => 4695 [post_author] => 5 [post_date] => 2022-04-26 09:54:07 [post_date_gmt] => 2022-04-26 09:54:07 [post_content] => [post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement [to_ping] => [pinged] => [post_modified] => 2023-05-17 10:24:57 [post_modified_gmt] => 2023-05-17 10:24:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4695 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [365] => WP_Post Object ( [ID] => 4691 [post_author] => 5 [post_date] => 2022-04-25 12:59:51 [post_date_gmt] => 2022-04-25 12:59:51 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:37:35 [post_modified_gmt] => 2022-09-26 14:37:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4691 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [366] => WP_Post Object ( [ID] => 4690 [post_author] => 5 [post_date] => 2022-04-25 12:53:48 [post_date_gmt] => 2022-04-25 12:53:48 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:46:23 [post_modified_gmt] => 2022-08-11 09:46:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4690 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [367] => WP_Post Object ( [ID] => 4689 [post_author] => 5 [post_date] => 2022-04-25 12:48:26 [post_date_gmt] => 2022-04-25 12:48:26 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:46:36 [post_modified_gmt] => 2022-08-11 09:46:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4689 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [368] => WP_Post Object ( [ID] => 4688 [post_author] => 5 [post_date] => 2022-04-25 12:44:13 [post_date_gmt] => 2022-04-25 12:44:13 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:46:53 [post_modified_gmt] => 2022-08-11 09:46:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4688 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [369] => WP_Post Object ( [ID] => 4687 [post_author] => 5 [post_date] => 2022-04-25 12:41:22 [post_date_gmt] => 2022-04-25 12:41:22 [post_content] => [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:47:22 [post_modified_gmt] => 2022-08-11 09:47:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4687 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [370] => WP_Post Object ( [ID] => 4686 [post_author] => 5 [post_date] => 2022-04-25 12:37:16 [post_date_gmt] => 2022-04-25 12:37:16 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:47:39 [post_modified_gmt] => 2022-08-11 09:47:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4686 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [371] => WP_Post Object ( [ID] => 4685 [post_author] => 5 [post_date] => 2022-04-25 12:29:54 [post_date_gmt] => 2022-04-25 12:29:54 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses [to_ping] => [pinged] => [post_modified] => 2022-09-29 11:26:17 [post_modified_gmt] => 2022-09-29 11:26:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4685 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [372] => WP_Post Object ( [ID] => 4684 [post_author] => 5 [post_date] => 2022-04-25 12:25:07 [post_date_gmt] => 2022-04-25 12:25:07 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-12-14 13:46:43 [post_modified_gmt] => 2022-12-14 13:46:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4684 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [373] => WP_Post Object ( [ID] => 4683 [post_author] => 5 [post_date] => 2022-04-25 12:03:48 [post_date_gmt] => 2022-04-25 12:03:48 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-03-28 14:00:20 [post_modified_gmt] => 2023-03-28 14:00:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4683 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [374] => WP_Post Object ( [ID] => 4682 [post_author] => 5 [post_date] => 2022-04-25 11:56:46 [post_date_gmt] => 2022-04-25 11:56:46 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:54:40 [post_modified_gmt] => 2022-10-12 12:54:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4682 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [375] => WP_Post Object ( [ID] => 4681 [post_author] => 5 [post_date] => 2022-04-25 11:39:24 [post_date_gmt] => 2022-04-25 11:39:24 [post_content] => [post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-27 08:32:10 [post_modified_gmt] => 2023-04-27 08:32:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4681 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [376] => WP_Post Object ( [ID] => 4680 [post_author] => 5 [post_date] => 2022-04-25 11:17:54 [post_date_gmt] => 2022-04-25 11:17:54 [post_content] => [post_title] => Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement [to_ping] => [pinged] => [post_modified] => 2022-08-11 09:52:04 [post_modified_gmt] => 2022-08-11 09:52:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4680 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [377] => WP_Post Object ( [ID] => 4661 [post_author] => 5 [post_date] => 2022-04-20 08:13:06 [post_date_gmt] => 2022-04-20 08:13:06 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-10-03 13:53:17 [post_modified_gmt] => 2022-10-03 13:53:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4661 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [378] => WP_Post Object ( [ID] => 4147 [post_author] => 5 [post_date] => 2022-04-18 12:53:51 [post_date_gmt] => 2022-04-18 12:53:51 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:24:43 [post_modified_gmt] => 2022-12-15 16:24:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4147 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [379] => WP_Post Object ( [ID] => 4601 [post_author] => 5 [post_date] => 2022-04-18 10:40:48 [post_date_gmt] => 2022-04-18 10:40:48 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:44:46 [post_modified_gmt] => 2022-04-18 10:44:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4601 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [380] => WP_Post Object ( [ID] => 4148 [post_author] => 5 [post_date] => 2022-04-12 08:59:45 [post_date_gmt] => 2022-04-12 08:59:45 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:25:17 [post_modified_gmt] => 2023-05-01 14:25:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4148 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [381] => WP_Post Object ( [ID] => 4580 [post_author] => 5 [post_date] => 2022-03-31 14:34:38 [post_date_gmt] => 2022-03-31 14:34:38 [post_content] => [post_title] => CEPI – CureVac, Framework Partnering Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-curevac-framework-partnering-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:33:29 [post_modified_gmt] => 2023-04-28 13:33:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4580 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [382] => WP_Post Object ( [ID] => 4519 [post_author] => 5 [post_date] => 2022-03-25 12:48:09 [post_date_gmt] => 2022-03-25 12:48:09 [post_content] => [post_title] => Gates Foundation Sample Grant Terms & Conditions [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gates-foundation-sample-grant-terms-conditions [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:25:09 [post_modified_gmt] => 2022-12-15 16:25:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4519 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [383] => WP_Post Object ( [ID] => 4516 [post_author] => 5 [post_date] => 2022-03-23 09:07:57 [post_date_gmt] => 2022-03-23 09:07:57 [post_content] => [post_title] => CARB-X Research Subaward Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => carb-x-research-subaward-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-27 12:47:08 [post_modified_gmt] => 2023-04-27 12:47:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4516 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [384] => WP_Post Object ( [ID] => 4491 [post_author] => 5 [post_date] => 2022-03-17 15:42:04 [post_date_gmt] => 2022-03-17 15:42:04 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-12 [to_ping] => [pinged] => [post_modified] => 2022-03-17 15:42:04 [post_modified_gmt] => 2022-03-17 15:42:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4491 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [385] => WP_Post Object ( [ID] => 4490 [post_author] => 5 [post_date] => 2022-03-17 15:37:26 [post_date_gmt] => 2022-03-17 15:37:26 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-11 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:12:35 [post_modified_gmt] => 2022-10-12 11:12:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4490 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [386] => WP_Post Object ( [ID] => 4489 [post_author] => 5 [post_date] => 2022-03-17 15:33:45 [post_date_gmt] => 2022-03-17 15:33:45 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-10 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:28:24 [post_modified_gmt] => 2023-04-28 13:28:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4489 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [387] => WP_Post Object ( [ID] => 4488 [post_author] => 5 [post_date] => 2022-03-17 15:11:54 [post_date_gmt] => 2022-03-17 15:11:54 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-9 [to_ping] => [pinged] => [post_modified] => 2022-05-23 10:48:00 [post_modified_gmt] => 2022-05-23 10:48:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4488 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [388] => WP_Post Object ( [ID] => 4487 [post_author] => 5 [post_date] => 2022-03-17 14:58:23 [post_date_gmt] => 2022-03-17 14:58:23 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-8 [to_ping] => [pinged] => [post_modified] => 2022-03-17 15:04:54 [post_modified_gmt] => 2022-03-17 15:04:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4487 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [389] => WP_Post Object ( [ID] => 4486 [post_author] => 5 [post_date] => 2022-03-17 14:50:08 [post_date_gmt] => 2022-03-17 14:50:08 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-7 [to_ping] => [pinged] => [post_modified] => 2022-03-17 14:50:08 [post_modified_gmt] => 2022-03-17 14:50:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4486 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [390] => WP_Post Object ( [ID] => 4485 [post_author] => 5 [post_date] => 2022-03-17 14:43:27 [post_date_gmt] => 2022-03-17 14:43:27 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-6 [to_ping] => [pinged] => [post_modified] => 2023-04-27 13:01:18 [post_modified_gmt] => 2023-04-27 13:01:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4485 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [391] => WP_Post Object ( [ID] => 4484 [post_author] => 5 [post_date] => 2022-03-17 13:56:19 [post_date_gmt] => 2022-03-17 13:56:19 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-5 [to_ping] => [pinged] => [post_modified] => 2022-09-29 10:50:14 [post_modified_gmt] => 2022-09-29 10:50:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4484 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [392] => WP_Post Object ( [ID] => 4483 [post_author] => 5 [post_date] => 2022-03-17 13:21:19 [post_date_gmt] => 2022-03-17 13:21:19 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-4 [to_ping] => [pinged] => [post_modified] => 2022-03-17 13:22:33 [post_modified_gmt] => 2022-03-17 13:22:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4483 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [393] => WP_Post Object ( [ID] => 4482 [post_author] => 5 [post_date] => 2022-03-17 12:43:13 [post_date_gmt] => 2022-03-17 12:43:13 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-3 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:55:30 [post_modified_gmt] => 2022-10-12 12:55:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4482 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [394] => WP_Post Object ( [ID] => 4481 [post_author] => 5 [post_date] => 2022-03-17 12:28:49 [post_date_gmt] => 2022-03-17 12:28:49 [post_content] => [post_title] => Cellscript – BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense-2 [to_ping] => [pinged] => [post_modified] => 2022-07-13 12:08:00 [post_modified_gmt] => 2022-07-13 12:08:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4481 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [395] => WP_Post Object ( [ID] => 4469 [post_author] => 5 [post_date] => 2022-03-17 10:55:42 [post_date_gmt] => 2022-03-17 10:55:42 [post_content] => [post_title] => Cellscript - BioNTech mRNA Technology Patent Sublicense [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cellscript-biontech-mrna-technology-patent-sublicense [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:27:06 [post_modified_gmt] => 2023-04-28 13:27:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4469 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [396] => WP_Post Object ( [ID] => 4223 [post_author] => 5 [post_date] => 2022-03-04 09:43:58 [post_date_gmt] => 2022-03-04 09:43:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-05-31 18:00:18 [post_modified_gmt] => 2022-05-31 18:00:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4223 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [397] => WP_Post Object ( [ID] => 4222 [post_author] => 5 [post_date] => 2022-03-04 09:14:41 [post_date_gmt] => 2022-03-04 09:14:41 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:13:06 [post_modified_gmt] => 2022-10-12 11:13:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4222 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [398] => WP_Post Object ( [ID] => 4221 [post_author] => 5 [post_date] => 2022-03-04 09:05:29 [post_date_gmt] => 2022-03-04 09:05:29 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:36:15 [post_modified_gmt] => 2022-09-26 14:36:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [399] => WP_Post Object ( [ID] => 4220 [post_author] => 5 [post_date] => 2022-03-04 08:47:04 [post_date_gmt] => 2022-03-04 08:47:04 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:22:53 [post_modified_gmt] => 2023-04-28 13:22:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4220 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [400] => WP_Post Object ( [ID] => 4219 [post_author] => 5 [post_date] => 2022-03-04 08:02:15 [post_date_gmt] => 2022-03-04 08:02:15 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:55:41 [post_modified_gmt] => 2023-01-04 15:55:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4219 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [401] => WP_Post Object ( [ID] => 4218 [post_author] => 5 [post_date] => 2022-03-03 14:17:53 [post_date_gmt] => 2022-03-03 14:17:53 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:10:14 [post_modified_gmt] => 2023-01-04 15:10:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4218 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [402] => WP_Post Object ( [ID] => 4217 [post_author] => 5 [post_date] => 2022-03-03 13:59:58 [post_date_gmt] => 2022-03-03 13:59:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-05-31 17:56:43 [post_modified_gmt] => 2022-05-31 17:56:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4217 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [403] => WP_Post Object ( [ID] => 4216 [post_author] => 5 [post_date] => 2022-03-03 13:45:21 [post_date_gmt] => 2022-03-03 13:45:21 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-05-31 17:56:00 [post_modified_gmt] => 2022-05-31 17:56:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4216 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [404] => WP_Post Object ( [ID] => 4215 [post_author] => 5 [post_date] => 2022-03-03 13:31:56 [post_date_gmt] => 2022-03-03 13:31:56 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-29 10:41:55 [post_modified_gmt] => 2022-09-29 10:41:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4215 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [405] => WP_Post Object ( [ID] => 4214 [post_author] => 5 [post_date] => 2022-03-03 12:54:33 [post_date_gmt] => 2022-03-03 12:54:33 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:21:12 [post_modified_gmt] => 2023-04-28 13:21:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4214 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [406] => WP_Post Object ( [ID] => 4213 [post_author] => 5 [post_date] => 2022-03-03 10:54:01 [post_date_gmt] => 2022-03-03 10:54:01 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-05-31 15:05:32 [post_modified_gmt] => 2022-05-31 15:05:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4213 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [407] => WP_Post Object ( [ID] => 4212 [post_author] => 5 [post_date] => 2022-03-02 14:54:16 [post_date_gmt] => 2022-03-02 14:54:16 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:20:51 [post_modified_gmt] => 2023-04-28 13:20:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4212 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [408] => WP_Post Object ( [ID] => 4210 [post_author] => 5 [post_date] => 2022-03-02 13:14:31 [post_date_gmt] => 2022-03-02 13:14:31 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-07-13 12:03:49 [post_modified_gmt] => 2022-07-13 12:03:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4210 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [409] => WP_Post Object ( [ID] => 4209 [post_author] => 5 [post_date] => 2022-03-02 12:07:13 [post_date_gmt] => 2022-03-02 12:07:13 [post_content] => [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement [to_ping] => [pinged] => [post_modified] => 2022-10-13 13:16:54 [post_modified_gmt] => 2022-10-13 13:16:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4209 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [410] => WP_Post Object ( [ID] => 4205 [post_author] => 5 [post_date] => 2022-02-28 15:24:19 [post_date_gmt] => 2022-02-28 15:24:19 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-10-12 12:59:13 [post_modified_gmt] => 2022-10-12 12:59:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4205 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [411] => WP_Post Object ( [ID] => 4204 [post_author] => 5 [post_date] => 2022-02-28 14:53:11 [post_date_gmt] => 2022-02-28 14:53:11 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-14 13:07:32 [post_modified_gmt] => 2022-12-14 13:07:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4204 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [412] => WP_Post Object ( [ID] => 4201 [post_author] => 5 [post_date] => 2022-02-28 13:33:22 [post_date_gmt] => 2022-02-28 13:33:22 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-10 13:13:57 [post_modified_gmt] => 2023-01-10 13:13:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4201 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [413] => WP_Post Object ( [ID] => 4200 [post_author] => 5 [post_date] => 2022-02-28 13:13:29 [post_date_gmt] => 2022-02-28 13:13:29 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:13:52 [post_modified_gmt] => 2022-10-12 11:13:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4200 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [414] => WP_Post Object ( [ID] => 4161 [post_author] => 5 [post_date] => 2022-02-02 13:48:58 [post_date_gmt] => 2022-02-02 13:48:58 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-12-15 09:53:28 [post_modified_gmt] => 2022-12-15 09:53:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4161 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [415] => WP_Post Object ( [ID] => 4159 [post_author] => 5 [post_date] => 2022-02-02 13:10:48 [post_date_gmt] => 2022-02-02 13:10:48 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-10-12 11:15:11 [post_modified_gmt] => 2022-10-12 11:15:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4159 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [416] => WP_Post Object ( [ID] => 4158 [post_author] => 5 [post_date] => 2022-02-02 13:00:08 [post_date_gmt] => 2022-02-02 13:00:08 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-03 12:48:45 [post_modified_gmt] => 2023-01-03 12:48:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4158 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [417] => WP_Post Object ( [ID] => 4157 [post_author] => 5 [post_date] => 2022-02-02 12:54:56 [post_date_gmt] => 2022-02-02 12:54:56 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:13:37 [post_modified_gmt] => 2022-04-18 13:13:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4157 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [418] => WP_Post Object ( [ID] => 4156 [post_author] => 5 [post_date] => 2022-02-02 12:36:42 [post_date_gmt] => 2022-02-02 12:36:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:10:37 [post_modified_gmt] => 2023-01-04 15:10:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4156 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [419] => WP_Post Object ( [ID] => 4155 [post_author] => 5 [post_date] => 2022-02-02 12:19:16 [post_date_gmt] => 2022-02-02 12:19:16 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:12:26 [post_modified_gmt] => 2022-04-18 13:12:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4155 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [420] => WP_Post Object ( [ID] => 4154 [post_author] => 5 [post_date] => 2022-02-02 12:13:41 [post_date_gmt] => 2022-02-02 12:13:41 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-02-02 12:13:41 [post_modified_gmt] => 2022-02-02 12:13:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4154 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [421] => WP_Post Object ( [ID] => 4153 [post_author] => 5 [post_date] => 2022-02-02 12:10:13 [post_date_gmt] => 2022-02-02 12:10:13 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-09-29 11:28:28 [post_modified_gmt] => 2022-09-29 11:28:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4153 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [422] => WP_Post Object ( [ID] => 4152 [post_author] => 5 [post_date] => 2022-02-02 11:51:54 [post_date_gmt] => 2022-02-02 11:51:54 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:57:07 [post_modified_gmt] => 2022-09-26 14:57:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4152 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [423] => WP_Post Object ( [ID] => 4151 [post_author] => 5 [post_date] => 2022-02-02 11:39:24 [post_date_gmt] => 2022-02-02 11:39:24 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-10-12 13:00:22 [post_modified_gmt] => 2022-10-12 13:00:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4151 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [424] => WP_Post Object ( [ID] => 4150 [post_author] => 5 [post_date] => 2022-02-02 10:24:30 [post_date_gmt] => 2022-02-02 10:24:30 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:01:03 [post_modified_gmt] => 2022-04-18 13:01:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4150 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [425] => WP_Post Object ( [ID] => 4149 [post_author] => 5 [post_date] => 2022-02-02 10:15:42 [post_date_gmt] => 2022-02-02 10:15:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:24:14 [post_modified_gmt] => 2023-05-01 14:24:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4149 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [426] => WP_Post Object ( [ID] => 4146 [post_author] => 5 [post_date] => 2022-02-02 07:28:42 [post_date_gmt] => 2022-02-02 07:28:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-10-13 13:18:01 [post_modified_gmt] => 2022-10-13 13:18:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4146 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [427] => WP_Post Object ( [ID] => 4141 [post_author] => 5 [post_date] => 2022-01-31 14:31:23 [post_date_gmt] => 2022-01-31 14:31:23 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:40:20 [post_modified_gmt] => 2023-01-10 10:40:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4141 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [428] => WP_Post Object ( [ID] => 4140 [post_author] => 5 [post_date] => 2022-01-31 14:22:03 [post_date_gmt] => 2022-01-31 14:22:03 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:54:15 [post_modified_gmt] => 2023-01-10 10:54:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4140 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [429] => WP_Post Object ( [ID] => 4139 [post_author] => 5 [post_date] => 2022-01-31 14:18:32 [post_date_gmt] => 2022-01-31 14:18:32 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:58:00 [post_modified_gmt] => 2023-01-10 10:58:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4139 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [430] => WP_Post Object ( [ID] => 4138 [post_author] => 5 [post_date] => 2022-01-31 14:09:33 [post_date_gmt] => 2022-01-31 14:09:33 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:59:39 [post_modified_gmt] => 2023-01-10 10:59:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4138 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [431] => WP_Post Object ( [ID] => 4137 [post_author] => 5 [post_date] => 2022-01-31 13:53:37 [post_date_gmt] => 2022-01-31 13:53:37 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:02:20 [post_modified_gmt] => 2023-01-10 11:02:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4137 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [432] => WP_Post Object ( [ID] => 4136 [post_author] => 5 [post_date] => 2022-01-31 13:42:47 [post_date_gmt] => 2022-01-31 13:42:47 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:01:51 [post_modified_gmt] => 2023-01-10 11:01:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4136 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [433] => WP_Post Object ( [ID] => 4135 [post_author] => 5 [post_date] => 2022-01-31 13:25:08 [post_date_gmt] => 2022-01-31 13:25:08 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:59:11 [post_modified_gmt] => 2023-01-10 10:59:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4135 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [434] => WP_Post Object ( [ID] => 4134 [post_author] => 5 [post_date] => 2022-01-31 12:56:28 [post_date_gmt] => 2022-01-31 12:56:28 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:58:24 [post_modified_gmt] => 2023-01-10 10:58:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4134 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [435] => WP_Post Object ( [ID] => 4133 [post_author] => 5 [post_date] => 2022-01-31 12:22:56 [post_date_gmt] => 2022-01-31 12:22:56 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:56:11 [post_modified_gmt] => 2023-01-10 10:56:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4133 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [436] => WP_Post Object ( [ID] => 4131 [post_author] => 5 [post_date] => 2022-01-29 16:21:19 [post_date_gmt] => 2022-01-29 16:21:19 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:35:36 [post_modified_gmt] => 2023-04-28 13:35:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4131 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [437] => WP_Post Object ( [ID] => 4130 [post_author] => 5 [post_date] => 2022-01-29 15:34:50 [post_date_gmt] => 2022-01-29 15:34:50 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-01-10 10:57:20 [post_modified_gmt] => 2023-01-10 10:57:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4130 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [438] => WP_Post Object ( [ID] => 4129 [post_author] => 5 [post_date] => 2022-01-28 14:43:06 [post_date_gmt] => 2022-01-28 14:43:06 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:34:27 [post_modified_gmt] => 2023-04-28 13:34:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4129 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [439] => WP_Post Object ( [ID] => 4128 [post_author] => 5 [post_date] => 2022-01-28 13:38:44 [post_date_gmt] => 2022-01-28 13:38:44 [post_content] => [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement [to_ping] => [pinged] => [post_modified] => 2023-01-10 11:07:15 [post_modified_gmt] => 2023-01-10 11:07:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4128 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [440] => WP_Post Object ( [ID] => 4113 [post_author] => 5 [post_date] => 2022-01-19 09:21:03 [post_date_gmt] => 2022-01-19 09:21:03 [post_content] => [post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => autm-model-inter-institutional-research-collaboration-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:32:06 [post_modified_gmt] => 2022-09-26 14:32:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4113 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [441] => WP_Post Object ( [ID] => 4112 [post_author] => 5 [post_date] => 2022-01-18 14:43:23 [post_date_gmt] => 2022-01-18 14:43:23 [post_content] => [post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => autm-model-inter-institutional-research-collaboration-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-19 09:17:01 [post_modified_gmt] => 2022-01-19 09:17:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4112 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [442] => WP_Post Object ( [ID] => 4105 [post_author] => 5 [post_date] => 2022-01-18 13:30:40 [post_date_gmt] => 2022-01-18 13:30:40 [post_content] => [post_title] => AUTM Model Inter-Institutional Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => autm-model-inter-institutional-research-collaboration-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:14:12 [post_modified_gmt] => 2023-04-28 13:14:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4105 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [443] => WP_Post Object ( [ID] => 4098 [post_author] => 5 [post_date] => 2022-01-12 14:27:12 [post_date_gmt] => 2022-01-12 14:27:12 [post_content] => [post_title] => Academic Institution – Company, Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => academic-institution-company-research-collaboration-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-12 14:27:12 [post_modified_gmt] => 2022-01-12 14:27:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4098 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [444] => WP_Post Object ( [ID] => 4095 [post_author] => 5 [post_date] => 2022-01-12 13:39:41 [post_date_gmt] => 2022-01-12 13:39:41 [post_content] => [post_title] => Academic Institution – Company, Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => academic-institution-company-research-collaboration-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-04-04 15:28:51 [post_modified_gmt] => 2023-04-04 15:28:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4095 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [445] => WP_Post Object ( [ID] => 4094 [post_author] => 5 [post_date] => 2022-01-12 13:19:48 [post_date_gmt] => 2022-01-12 13:19:48 [post_content] => [post_title] => Academic Institution – Company, Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => academic-institution-company-research-collaboration-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-04-04 15:28:27 [post_modified_gmt] => 2023-04-04 15:28:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4094 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [446] => WP_Post Object ( [ID] => 4093 [post_author] => 5 [post_date] => 2022-01-12 13:01:38 [post_date_gmt] => 2022-01-12 13:01:38 [post_content] => [post_title] => Academic Institution - Company, Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => academic-institution-company-research-collaboration-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-07-13 13:36:58 [post_modified_gmt] => 2022-07-13 13:36:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4093 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [447] => WP_Post Object ( [ID] => 4092 [post_author] => 5 [post_date] => 2022-01-12 12:33:49 [post_date_gmt] => 2022-01-12 12:33:49 [post_content] => [post_title] => Academic Institution - Company, Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => academic-institution-company-research-collaboration-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:02:39 [post_modified_gmt] => 2023-04-28 13:02:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4092 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [448] => WP_Post Object ( [ID] => 4090 [post_author] => 5 [post_date] => 2022-01-12 11:48:32 [post_date_gmt] => 2022-01-12 11:48:32 [post_content] => [post_title] => Academic Institution - Company, Research Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => academic-institution-company-research-collaboration-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-27 12:45:00 [post_modified_gmt] => 2023-04-27 12:45:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4090 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [449] => WP_Post Object ( [ID] => 4089 [post_author] => 5 [post_date] => 2022-01-11 13:35:45 [post_date_gmt] => 2022-01-11 13:35:45 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-03-29 08:52:55 [post_modified_gmt] => 2023-03-29 08:52:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4089 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [450] => WP_Post Object ( [ID] => 4086 [post_author] => 5 [post_date] => 2022-01-11 12:13:55 [post_date_gmt] => 2022-01-11 12:13:55 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:58:11 [post_modified_gmt] => 2023-01-04 15:58:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4086 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [451] => WP_Post Object ( [ID] => 4085 [post_author] => 5 [post_date] => 2022-01-11 12:01:14 [post_date_gmt] => 2022-01-11 12:01:14 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-01-11 12:01:14 [post_modified_gmt] => 2022-01-11 12:01:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4085 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [452] => WP_Post Object ( [ID] => 4082 [post_author] => 5 [post_date] => 2022-01-11 09:06:56 [post_date_gmt] => 2022-01-11 09:06:56 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-11 09:07:31 [post_modified_gmt] => 2022-01-11 09:07:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4082 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [453] => WP_Post Object ( [ID] => 4081 [post_author] => 5 [post_date] => 2022-01-11 08:42:56 [post_date_gmt] => 2022-01-11 08:42:56 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-09-29 12:31:24 [post_modified_gmt] => 2022-09-29 12:31:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4081 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [454] => WP_Post Object ( [ID] => 4080 [post_author] => 5 [post_date] => 2022-01-11 08:32:58 [post_date_gmt] => 2022-01-11 08:32:58 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-11 15:17:30 [post_modified_gmt] => 2022-01-11 15:17:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4080 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [455] => WP_Post Object ( [ID] => 4079 [post_author] => 5 [post_date] => 2022-01-11 08:07:49 [post_date_gmt] => 2022-01-11 08:07:49 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:46:00 [post_modified_gmt] => 2023-05-01 14:46:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4079 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [456] => WP_Post Object ( [ID] => 4078 [post_author] => 5 [post_date] => 2022-01-11 07:42:00 [post_date_gmt] => 2022-01-11 07:42:00 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-10-12 13:01:56 [post_modified_gmt] => 2022-10-12 13:01:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4078 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [457] => WP_Post Object ( [ID] => 4077 [post_author] => 5 [post_date] => 2022-01-11 07:20:11 [post_date_gmt] => 2022-01-11 07:20:11 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:47:40 [post_modified_gmt] => 2023-04-27 11:47:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4077 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [458] => WP_Post Object ( [ID] => 4075 [post_author] => 5 [post_date] => 2022-01-11 05:59:46 [post_date_gmt] => 2022-01-11 05:59:46 [post_content] => [post_title] => University of Washington – Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-07-13 13:52:33 [post_modified_gmt] => 2022-07-13 13:52:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4075 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [459] => WP_Post Object ( [ID] => 4072 [post_author] => 5 [post_date] => 2022-01-08 13:16:04 [post_date_gmt] => 2022-01-08 13:16:04 [post_content] => [post_title] => University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-05-04 12:02:05 [post_modified_gmt] => 2023-05-04 12:02:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4072 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [460] => WP_Post Object ( [ID] => 4066 [post_author] => 5 [post_date] => 2022-01-07 11:35:15 [post_date_gmt] => 2022-01-07 11:35:15 [post_content] => [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => path-aridis-rotavirus-vaccine-development-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-12-16 13:30:48 [post_modified_gmt] => 2022-12-16 13:30:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4066 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [461] => WP_Post Object ( [ID] => 4065 [post_author] => 5 [post_date] => 2022-01-07 11:21:06 [post_date_gmt] => 2022-01-07 11:21:06 [post_content] => [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => path-aridis-rotavirus-vaccine-development-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-01-07 11:21:06 [post_modified_gmt] => 2022-01-07 11:21:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4065 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [462] => WP_Post Object ( [ID] => 4064 [post_author] => 5 [post_date] => 2022-01-07 10:57:29 [post_date_gmt] => 2022-01-07 10:57:29 [post_content] => [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => path-aridis-rotavirus-vaccine-development-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-01-07 10:57:29 [post_modified_gmt] => 2022-01-07 10:57:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4064 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [463] => WP_Post Object ( [ID] => 4063 [post_author] => 5 [post_date] => 2022-01-07 10:34:51 [post_date_gmt] => 2022-01-07 10:34:51 [post_content] => [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => path-aridis-rotavirus-vaccine-development-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-14 15:43:22 [post_modified_gmt] => 2022-12-14 15:43:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4063 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [464] => WP_Post Object ( [ID] => 4062 [post_author] => 5 [post_date] => 2022-01-07 10:03:12 [post_date_gmt] => 2022-01-07 10:03:12 [post_content] => [post_title] => PATH – Aridis, Rotavirus Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => path-aridis-rotavirus-vaccine-development-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-09-26 14:30:30 [post_modified_gmt] => 2022-09-26 14:30:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4062 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [465] => WP_Post Object ( [ID] => 4061 [post_author] => 5 [post_date] => 2022-01-07 09:46:42 [post_date_gmt] => 2022-01-07 09:46:42 [post_content] => [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => path-aridis-rotavirus-vaccine-development-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:39:45 [post_modified_gmt] => 2023-05-01 14:39:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4061 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [466] => WP_Post Object ( [ID] => 4060 [post_author] => 5 [post_date] => 2022-01-07 09:40:49 [post_date_gmt] => 2022-01-07 09:40:49 [post_content] => [post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => path-aridis-rotavirus-vaccine-development-agreement [to_ping] => [pinged] => [post_modified] => 2022-12-15 16:27:06 [post_modified_gmt] => 2022-12-15 16:27:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4060 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [467] => WP_Post Object ( [ID] => 4058 [post_author] => 5 [post_date] => 2022-01-04 14:25:52 [post_date_gmt] => 2022-01-04 14:25:52 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-01-03 12:47:11 [post_modified_gmt] => 2023-01-03 12:47:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4058 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [468] => WP_Post Object ( [ID] => 4054 [post_author] => 5 [post_date] => 2022-01-03 11:45:52 [post_date_gmt] => 2022-01-03 11:45:52 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20 [to_ping] => [pinged] => [post_modified] => 2022-12-15 14:45:07 [post_modified_gmt] => 2022-12-15 14:45:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4054 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [469] => WP_Post Object ( [ID] => 4051 [post_author] => 5 [post_date] => 2022-01-03 11:01:41 [post_date_gmt] => 2022-01-03 11:01:41 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:38:45 [post_modified_gmt] => 2023-05-01 14:38:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4051 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [470] => WP_Post Object ( [ID] => 4050 [post_author] => 5 [post_date] => 2022-01-03 10:49:32 [post_date_gmt] => 2022-01-03 10:49:32 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-01-03 10:56:55 [post_modified_gmt] => 2022-01-03 10:56:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4050 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [471] => WP_Post Object ( [ID] => 4047 [post_author] => 5 [post_date] => 2021-12-27 17:17:36 [post_date_gmt] => 2021-12-27 17:17:36 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-01-04 16:05:43 [post_modified_gmt] => 2023-01-04 16:05:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4047 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [472] => WP_Post Object ( [ID] => 4046 [post_author] => 5 [post_date] => 2021-12-27 17:10:47 [post_date_gmt] => 2021-12-27 17:10:47 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:13:16 [post_modified_gmt] => 2023-01-04 15:13:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4046 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [473] => WP_Post Object ( [ID] => 4045 [post_author] => 5 [post_date] => 2021-12-27 17:07:25 [post_date_gmt] => 2021-12-27 17:07:25 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-04-27 11:30:11 [post_modified_gmt] => 2023-04-27 11:30:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4045 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [474] => WP_Post Object ( [ID] => 4043 [post_author] => 5 [post_date] => 2021-12-27 16:47:54 [post_date_gmt] => 2021-12-27 16:47:54 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-12-27 16:47:54 [post_modified_gmt] => 2021-12-27 16:47:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4043 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [475] => WP_Post Object ( [ID] => 4042 [post_author] => 5 [post_date] => 2021-12-27 16:41:56 [post_date_gmt] => 2021-12-27 16:41:56 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-09-29 12:25:56 [post_modified_gmt] => 2022-09-29 12:25:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4042 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [476] => WP_Post Object ( [ID] => 4041 [post_author] => 5 [post_date] => 2021-12-27 16:28:21 [post_date_gmt] => 2021-12-27 16:28:21 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9 [to_ping] => [pinged] => [post_modified] => 2023-03-21 11:33:53 [post_modified_gmt] => 2023-03-21 11:33:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4041 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [477] => WP_Post Object ( [ID] => 4040 [post_author] => 5 [post_date] => 2021-12-27 15:24:04 [post_date_gmt] => 2021-12-27 15:24:04 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8 [to_ping] => [pinged] => [post_modified] => 2023-03-21 11:34:34 [post_modified_gmt] => 2023-03-21 11:34:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4040 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [478] => WP_Post Object ( [ID] => 4038 [post_author] => 5 [post_date] => 2021-12-27 15:08:30 [post_date_gmt] => 2021-12-27 15:08:30 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-04-05 12:35:46 [post_modified_gmt] => 2023-04-05 12:35:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4038 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [479] => WP_Post Object ( [ID] => 4036 [post_author] => 5 [post_date] => 2021-12-26 17:01:45 [post_date_gmt] => 2021-12-26 17:01:45 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-03-21 11:31:29 [post_modified_gmt] => 2023-03-21 11:31:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4036 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [480] => WP_Post Object ( [ID] => 4035 [post_author] => 5 [post_date] => 2021-12-26 16:47:36 [post_date_gmt] => 2021-12-26 16:47:36 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-16 13:28:18 [post_modified_gmt] => 2022-12-16 13:28:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4035 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [481] => WP_Post Object ( [ID] => 4032 [post_author] => 5 [post_date] => 2021-12-26 16:32:27 [post_date_gmt] => 2021-12-26 16:32:27 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3 [to_ping] => [pinged] => [post_modified] => 2023-05-01 14:37:25 [post_modified_gmt] => 2023-05-01 14:37:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4032 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [482] => WP_Post Object ( [ID] => 4029 [post_author] => 5 [post_date] => 2021-12-21 12:22:08 [post_date_gmt] => 2021-12-21 12:22:08 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-05 12:36:19 [post_modified_gmt] => 2023-04-05 12:36:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4029 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [483] => WP_Post Object ( [ID] => 4028 [post_author] => 5 [post_date] => 2021-12-21 11:55:28 [post_date_gmt] => 2021-12-21 11:55:28 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement [to_ping] => [pinged] => [post_modified] => 2023-04-05 12:35:05 [post_modified_gmt] => 2023-04-05 12:35:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4028 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [484] => WP_Post Object ( [ID] => 4024 [post_author] => 5 [post_date] => 2021-12-15 15:33:17 [post_date_gmt] => 2021-12-15 15:33:17 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22 [to_ping] => [pinged] => [post_modified] => 2021-12-15 15:33:17 [post_modified_gmt] => 2021-12-15 15:33:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4024 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [485] => WP_Post Object ( [ID] => 4022 [post_author] => 5 [post_date] => 2021-12-15 14:49:36 [post_date_gmt] => 2021-12-15 14:49:36 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:43:03 [post_modified_gmt] => 2023-04-28 13:43:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4022 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [486] => WP_Post Object ( [ID] => 4021 [post_author] => 5 [post_date] => 2021-12-15 14:31:00 [post_date_gmt] => 2021-12-15 14:31:00 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19 [to_ping] => [pinged] => [post_modified] => 2023-03-21 13:06:46 [post_modified_gmt] => 2023-03-21 13:06:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4021 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [487] => WP_Post Object ( [ID] => 4020 [post_author] => 5 [post_date] => 2021-12-15 14:24:47 [post_date_gmt] => 2021-12-15 14:24:47 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18 [to_ping] => [pinged] => [post_modified] => 2023-01-04 15:13:47 [post_modified_gmt] => 2023-01-04 15:13:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4020 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [488] => WP_Post Object ( [ID] => 4017 [post_author] => 5 [post_date] => 2021-12-15 13:22:49 [post_date_gmt] => 2021-12-15 13:22:49 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2021-12-15 13:22:49 [post_modified_gmt] => 2021-12-15 13:22:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4017 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [489] => WP_Post Object ( [ID] => 4016 [post_author] => 5 [post_date] => 2021-12-15 13:20:07 [post_date_gmt] => 2021-12-15 13:20:07 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-09-29 10:54:29 [post_modified_gmt] => 2022-09-29 10:54:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4016 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [490] => WP_Post Object ( [ID] => 4014 [post_author] => 5 [post_date] => 2021-12-15 12:33:09 [post_date_gmt] => 2021-12-15 12:33:09 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:42:36 [post_modified_gmt] => 2023-04-28 13:42:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4014 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [491] => WP_Post Object ( [ID] => 4013 [post_author] => 5 [post_date] => 2021-12-15 12:16:20 [post_date_gmt] => 2021-12-15 12:16:20 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2023-03-31 09:12:31 [post_modified_gmt] => 2023-03-31 09:12:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4013 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [492] => WP_Post Object ( [ID] => 4011 [post_author] => 5 [post_date] => 2021-12-14 15:21:54 [post_date_gmt] => 2021-12-14 15:21:54 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-07-13 09:25:12 [post_modified_gmt] => 2022-07-13 09:25:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4011 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [493] => WP_Post Object ( [ID] => 4009 [post_author] => 5 [post_date] => 2021-12-14 15:10:51 [post_date_gmt] => 2021-12-14 15:10:51 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-and-gsk-collaboration-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-04-28 13:42:14 [post_modified_gmt] => 2023-04-28 13:42:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4009 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [494] => WP_Post Object ( [ID] => 4007 [post_author] => 5 [post_date] => 2021-12-14 08:51:32 [post_date_gmt] => 2021-12-14 08:51:32 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-12-14 08:51:44 [post_modified_gmt] => 2021-12-14 08:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4007 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [495] => WP_Post Object ( [ID] => 4006 [post_author] => 5 [post_date] => 2021-12-14 08:16:01 [post_date_gmt] => 2021-12-14 08:16:01 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2023-04-05 10:44:31 [post_modified_gmt] => 2023-04-05 10:44:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4006 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [496] => WP_Post Object ( [ID] => 4004 [post_author] => 5 [post_date] => 2021-12-14 07:57:41 [post_date_gmt] => 2021-12-14 07:57:41 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2023-03-30 14:04:14 [post_modified_gmt] => 2023-03-30 14:04:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4004 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [497] => WP_Post Object ( [ID] => 4003 [post_author] => 5 [post_date] => 2021-12-13 18:36:53 [post_date_gmt] => 2021-12-13 18:36:53 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-12-14 14:03:19 [post_modified_gmt] => 2022-12-14 14:03:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4003 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [498] => WP_Post Object ( [ID] => 4002 [post_author] => 5 [post_date] => 2021-12-13 18:28:05 [post_date_gmt] => 2021-12-13 18:28:05 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-12-15 14:57:35 [post_modified_gmt] => 2022-12-15 14:57:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4002 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [499] => WP_Post Object ( [ID] => 4001 [post_author] => 5 [post_date] => 2021-12-13 14:55:46 [post_date_gmt] => 2021-12-13 14:55:46 [post_content] => [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2023-03-31 09:11:58 [post_modified_gmt] => 2023-03-31 09:11:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4001 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [500] => WP_Post Object ( [ID] => 3997 [post_author] => 5 [post_date] => 2021-12-13 14:24:49 [post_date_gmt] => 2021-12-13 14:24:49 [post_content] => [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2023-05-05 07:48:18 [post_modified_gmt] => 2023-05-05 07:48:18 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3997 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [501] => WP_Post Object ( [ID] => 3914 [post_author] => 5 [post_date] => 2021-11-30 12:34:32 [post_date_gmt] => 2021-11-30 12:34:32 [post_content] => [post_title] => MPP – BMS Sublicense & Tech Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => mpp-bms-sublicense-tech-transfer-agreement [to_ping] => [pinged] => [post_modified] => 2022-12-15 14:59:20 [post_modified_gmt] => 2022-12-15 14:59:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3914 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [502] => WP_Post Object ( [ID] => 3909 [post_author] => 5 [post_date] => 2021-11-22 13:29:28 [post_date_gmt] => 2021-11-22 13:29:28 [post_content] => [post_title] => Merck – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2023-01-27 14:48:06 [post_modified_gmt] => 2023-01-27 14:48:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3909 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [503] => WP_Post Object ( [ID] => 3908 [post_author] => 5 [post_date] => 2021-11-22 13:20:09 [post_date_gmt] => 2021-11-22 13:20:09 [post_content] => [post_title] => Merck – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2023-01-27 14:48:24 [post_modified_gmt] => 2023-01-27 14:48:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3908 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [504] => WP_Post Object ( [ID] => 3907 [post_author] => 5 [post_date] => 2021-11-22 13:07:49 [post_date_gmt] => 2021-11-22 13:07:49 [post_content] => [post_title] => Merck – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2023-01-27 14:48:44 [post_modified_gmt] => 2023-01-27 14:48:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3907 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [505] => WP_Post Object ( [ID] => 3906 [post_author] => 5 [post_date] => 2021-11-22 12:57:50 [post_date_gmt] => 2021-11-22 12:57:50 [post_content] => [post_title] => Merck – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2023-01-27 14:49:01 [post_modified_gmt] => 2023-01-27 14:49:01 [post_content_filtered] =>